Search is not available for this dataset
Therapeutic
stringlengths 8
15
| Format
stringlengths 3
52
| CH1 Isotype
stringclasses 15
values | VD LC
stringclasses 9
values | Highest_Clin_Trial (Oct '21)
stringclasses 12
values | Est. Status
stringclasses 4
values | Heavy Sequence
stringlengths 2
132
| Light Sequence
stringlengths 2
113
| Heavy Sequence (if bispec)
stringlengths 2
132
| Light Sequence (if bispec)
stringlengths 2
112
| 100% SI Structure
stringlengths 7
224
⌀ | 99% SI Structure
stringlengths 7
364
⌀ | 95-98% SI Structure
stringlengths 7
207
⌀ | Year Proposed
int64 1.99k
2.02k
| Year Recommended
stringclasses 30
values | Target
stringlengths 2
75
| Companies
stringlengths 2
1.7k
| Conditions Approved
stringlengths 2
277
| Conditions Active
stringlengths 2
910
| Conditions Discontinued
stringlengths 2
384
⌀ | Development Tech
stringlengths 2
149
| Notes
stringlengths 8
194
⌀ | Heavy Sequence second
stringlengths 127
158
⌀ | Light Sequence second
stringlengths 116
136
⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abagovomab | Whole mAb | G1 | Kappa | Phase-III | Discontinued | QVKLQESGAELARPGASVKLSCKASGYTFTNYWMQWVKQRPGQGLDWIGAIYPGDGNTRYTHKFKGKATLTADKSSSTAYMQLSSLASEDSGVYYCARGEGNYAWFAYWGQGTTVTVSS | DIELTQSPASLSASVGETVTITCQASENIYSYLAWHQQKQGKSPQLLVYNAKTLAGGVSSRFSGSGSGTHFSLKIKSLQPEDFGIYYCQHHYGILPTFGGGTKLEIK | na | na | null | null | null | 2,006 | 2007 | CA125 | Menarini | na | na | Ovarian cancer;Pancreatic cancer | na | null | Q VKLQ ESGA ELA RPGA SVKLSCK ASGY TFTNYWMQWVK QRPGQGLD WIGAI YPGDGNT RYTHKF KG KATLTA DKSSST AYMQLSS LASEDSG VYYCA RGEGN YAWFAYW GQGT TVTVS S | DI ELT QSPA SLSA SVGE TVTITCQ ASEN IYSYLAWHQ QKQGKSP QLLVYN AK T LAGG VSSRF SGSGSGT HFSLKIKS LQPEDF GIYYCQ HHYG IL PTFGGGT KLEI K |
Abciximab | Fab | G1 | Kappa | Approved | NFD | EVQLQQSGTVLARPGASVKMSCEASGYTFTNYWMHWVKQRPGQGLEWIGAIYPGNSDTSYIQKFKGKAKLTAVTSTTSVYMELSSLTNEDSAVYYCTLYDGYYVFAYWGQGTLVTVSA | EIVLTQSPVTLSVTPGDSVSLSCRASRDISNNLHWFQQTSHESPRLLIKYASQSMSGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQTNSWPYTFGGGTKLEIK | na | na | 6v4p:CD | null | null | 1,993 | 1994 | CD41_CD61 | Janssen Biologics BV;Eli Lilly | Coronary artery restenosis;Unstable angina pectoris | na | Arterial occlusive disorders;Myocardial infarction;Stroke | na | Sequence sourced through DrugBank. | EV QLQ QSG TVLA RPGA SVKMSCE ASGY TFTNYWMHWVK QRPGQGL EWIGAI YPGNSDTS YIQKF KGK AKLTAVT STT SVYMELS SLTNEDS AVYYCTL YDG YYVFAYW GQG TLVTVS A | E IVLT QSP VTLSV TPGD SVSLSCRA SRDISNNL HWFQQ TSHESP RLLIKYA SQSMSGIPS R FSGSGSGT DFTLSINSV ETEDF GMYFCQ QTNSWP YT FGGG TKLEI K |
Abelacimab | Whole mAb | G1 | Lambda | Phase-III | Active | QVQLLESGGGLVQPGGSLRLSCAASGFTFSTAAMSWVRQAPGKGLEWVSGISGSGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARELSYLYSGYYFDYWGQGTLVTVSS | QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNDVSWYQQLPGTAPKLLIYKNYNRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCSAWDQRQFDVVFGGGTKLTVL | na | na | null | null | 6r8x:CB | 2,018 | 2019 | F11 | Novartis;Anthos Therapeutics;Labcorp Drug Development;TIMI Study Group | na | Venous Thromboembolism; Stroke;Thrombosis | na | na | (Feb '22) Added in missing residues 97 and 98. (Jun '22) Added missing residues at start of VL CDR3. | Q VQLLES GGG LV QPGG SLRLSC AASGF TFST A A MSWVR QAPGKGL EWVS GISGSGSS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYC ARELSY LY SG YYFD YWGQG TLVTV SS | QSVLTQPPSASGTPGQ RVTISC SGSSSNIGSNDV SWYQ QLPGTAP KLLIYK NYNRPSGVPDRFSGSKSGTS A SLAI SGLQSEDEAD YYCS AWDQRQF DVVF GGGT KLTV L |
Abituzumab | Whole mAb | G2 | Kappa | Phase-II | Active | QVQLQQSGGELAKPGASVKVSCKASGYTFSSFWMHWVRQAPGQGLEWIGYINPRSGYTEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCASFLGRGAMDYWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKAPKLLIYYTSKIHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQGNTFPYTFGQGTKVEIK | na | na | null | null | null | 2,013 | 2014 | ITGAV | Merck | na | Colorectal cancer;Systemic scleroderma | Ovarian cancer;Prostate cancer;Solid tumours | na | 4o02 claims to be abituzumab (17E6), but is not | Q VQLQQ SGGE L AKPGA SVKVSCK ASGY TFSSFWMHWVR QAPGQG LEWIGYI NPRSGYTEYN EIF RDKA TMTT DTSTS TAYMELS SLRSEDT AVYYCASFL GRGAMDYWGQG TTVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQD ISNYLAWYQ QKPGKAP KLLIYYT SKIHSGVPSRFSGSGSGTD YTFTIS SLQ PEDIA TYYC QQGNTFP YT FGQGT KVEI K |
Abrezekimab | Fab | G1 | Kappa | Phase-I | Discontinued | QVTLKESGPVLVKPTETLTLTCTVSGFSLTNYHVQWIRQPPGKALEWLGVMWSDGDTSFNSVLKSRLTISRDTSKSQVVLTMTNMDPVDTATYYCARDGTIAAMDYFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCLASEDISNYLAWYQQKPGKAPKLLIYHTSRLQDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYRFPLTFGGGTKVEIK | na | na | null | null | null | 2,017 | 2018 | IL13 | UCB | na | na | Asthma | na | (Jun '22) Added missing FWH3 and CDRL3 residues | QV TLK ESGP VLV KPTE TLTLTCTV SGF S LT NYHVQWIR QPPGKA LEWLGVMW SDGDTSFN SVLKSRLTIS RDTSKS QVVLTMT NMDPVDT ATYYCA RDGT IAAMDY FDYWGQG TLVTVS S | DIQMTQSPSS LSA SVGD RVTITCL AS E D ISNYLAWYQ QKPGKAP KLLIYHT SRLQDGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQ QGY RFPLTF GGGT KVEI K |
Abrilumab | Whole mAb | G2 | Kappa | Phase-II | Discontinued | QVQLVQSGAEVKKPGASVKVSCKVSGYTLSDLSIHWVRQAPGKGLEWMGGFDPQDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLKSEDTAVYYCATGSSSSWFDPWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFANYYCQQANSFPWTFGQGTKVEIK | na | na | null | null | null | 2,014 | 2015 | α4β7 | Amgen;AstraZeneca | na | na | Crohn's disease;Ulcerative colitis | na | null | Q VQLVQ SGA EVK KPGA SVKVSCKV SGY T LSD LSIHWVR QAPGKG LEWMG G F DPQDGE TIYAQKF QG RVTMT EDTSTDT AYMELS SLKSEDT AVYYCA TGSSSSW F DPWGQG TLVTVS S | DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWYQ QKPGKAP KLLIYG ASNLESGVPSRFSGSGSGTD FTLTIS SLQ PEDFANYYCQ QANSFPW T FGQGT KVEI K |
Acapatamab | Bispecific scFv | na;na | Kappa;Lambda | Phase-I/II | Active | QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAIISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIK | EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS | QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL | None;None | None;None | None;None | 2,020 | 2021 | FOLH1;CD3E | Amgen | na | Cancers;Prostrate cancer;Metastatic cancer | na | BiTE Technology | null | Q VQLVES GGG LV KPGE SLRLSCA ASGF TF SD YYMYWVR QAPGKC LEWVAIIS DGG YYTYYS DI I KG RFTISR DNAKNS LYLQMN SLKAEDT AVYYC ARGFP LLR HGAMDYWGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCK ASQNVDTN VAWYQ QKPGQAPK SLIYSASYVYWD VPSRFSGSASGT DFTLTISS VQSEDF ATYYCQQ YDQ QLITF GCGT KLEI K |
Acasunlimab | Bispecific mAb | G1;G1 | Lambda;Kappa | Phase-I/II | Active | EVQLLEPGGGLVQPGGSLRLSCEASGSTFSTYAMSWVRQAPGKGLEWVSGFSGSGGFTFYADSVRGRFTISRDSSKNTLFLQMSSLRAEDTAVYYCAIPARGYNYGSFQHWGQGTLVTVSS | SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDNDRPSGLPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL | EVQLVESGGGLVQPGRSLRLSCTASGFSLNDYWMSWVRQAPGKGLEWVGYIDVGGSLYYAASVKGRFTISRDDSKSIAYLQMNSLKTEDTAVYYCARGGLTYGFDLWGQGTLVTVSS | DIVMTQSPSSLSASVGDRVTITCQASEDISSYLAWYQQKPGKAPKRLIYGASDLASGVPSRFSASGSGTDYTFTISSLQPEDIATYYCHYYATISGLGVAFGGGTKVEIK | None;None | None;None | None;None | 2,020 | 2021 | CD274;TNFRSF9 | Genmab;BioNTech | na | Solid tumours | na | na | null | E VQLL EPGGG LV QPGG SLRLSCE ASGST FSTYAMSWVR QAPGKG LEWVS GFSGSGG FTFYA DSVRG RFTISR DSSKN TLFLQMS SLRAEDT AVYYCAI PARGYNYGS FQH WGQG TLVTVS S | SY VL TQPPS VSV APGQ TARITC GGNNIGSK SVHWYQ QKPGQAP VLVVY DDNDRPSGLPERFSGSNSGN TATLTISRVE AGDE ADYYCQVWD SSSD HVVFG GGT KLTV L |
Acrixolimab | Whole mAb | G4 | Kappa | Phase-I | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFLRYAMHWVRQAPGKGLEWVAVISYDGRYKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTTTTFDSWGQGTLVTVSS | DIVMTQTPLSLPVTPGEAASISCRSSQSLLDSEDGNTYLDWYLQKPGQSPQLLIYTLSHRASGVPDRFSGSGSGTDFTLEISRVEAEDVGVYYCMQRRDFPFTFGQGTKVDIK | na | na | null | null | null | 2,022 | na | PDCD1 | Y-Biologics | na | Solid tumours | na | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFLRYAMHWVR QAPGKGL EWVAVIS YDGR YKYYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCTT T T FDSWGQ GTLVTVS S | DI VMT QTPLSLPVTPGEA ASISC RSSQ SLLD SEDGN TYLDWYL QKPGQSP QLLIYTLSH RASGVPDRFSGSGSGTD FTLEISRVE AEDV GVYYCMQ RRDFPF T FGQGT KVDI K |
Actoxumab | Whole mAb | G1 | Kappa | Phase-III | Discontinued | QVQLVESGGGVVQPGRSLRLSCAASGFSFSNYGMHWVRQAPGKGLEWVALIWYDGSNEDYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWGMVRGVIDVFDIWGQGTVVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQHKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGQGTKVEIK | na | na | null | null | null | 2,012 | 2013 | Toxin A | Bristol-Myers Squibb;Merck;University of Massachussets Medical School | na | na | Clostridium difficile | Medarex HuMAb Mouse | null | Q VQLVES GGG VV QPGR SLRLSC AASGF SF SNY GMHWVRQ APGKGL EWVALIWY DGSNEDYTDS VKGRFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RWGM VRGVIDVFDI WGQG TVVTVS S | DIQ MT QSPSS VSAS VGD RVTITCR ASQGIS SWLAWY QHKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYC QQANSFPW T FGQGT KVEI K |
Adalimumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK | na | na | 6cr1:HL/4nyl:AB:CD:EF:HL | 3wd5:HL | null | 1,999 | 2000 | TNFA | Abbvie;MedImmune;180 Life Sciences | Ankylosing spondylitis;Behcet's syndrome;Crohn's disease;Hidradenitis suppurativa;Juvenile rheumatoid arthritis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis;Rheumatoid arthritis;Spondylarthritis;Ulcerative colitis;Uveitis;Pyoderma | Dupuytren's contracture;Cognition disorders;Frozen shoulder;Non-alcoholic steatohepatitis | Interstitial cystitis | CAT Phage Display | null | E VQLVES GGG LV QPGR SLRLSC AASGFT F DDY AMHWVRQ APGKGL EWVSAITW NSGH ID YADSVE GRFTISR DNAKN SLYLQMNS LRAEDT AVYYCAKVSYL STASSLD Y WGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQG IRNYLAWYQ QKPGKAP KLLIYAA STLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDVATYYCQR YNRAPY T FGQGT KVEI K |
Adebrelimab | Whole mAb | G4 | Kappa | Preregistration | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGRIGPNSGFTSYNEKFKNRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGSSYDYFDYWGQGTTVTVSS | DIVLTQSPASLAVSPGQRATITCRASESVSIHGTHLMHWYQQKPGQPPKLLIYAASNLESGVPARFSGSGSGTDFTLTINPVEAEDTANYYCQQSFEDPLTFGQGTKLEIK | na | na | null | null | null | 2,019 | 2020 | PDL1 | Jiangsu Hengrui Medicine;Atridia | na | Small cell lung cancer;Non-small cell lung cancer;Oesophageal cancer;Cancer;Solid tumours | Haematological malignancies | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYWMHWVR QAPGQG LEWMGRI GPNSGFTSYNEKFKN RVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RGGSSYD YFD YWGQG TTVTVS S | D IVLTQ SPA SLAV SPGQ RATITCR ASE SVSIH G THLMHWYQ QKPGQPP KLLIYAA SNLESGVP ARFS GSGSGT DFTLTIN PVEAEDTA NYYCQQ SFEDPL T FGQGT KLEI K |
Adecatumumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDMGWGSGWRPYYYYGMDVWGQGTTVTVSS | ELQMTQSPSSLSASVGDRVTITCRTSQSISSYLNWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQPEDSATYYCQQSYDIPYTFGQGTKLEIK | na | na | null | null | null | 2,004 | 2004 | EPCAM | Micromet Inc;Merck Sorono;Amgen | na | na | Breast cancer;Colorectal cancer;Prostate cancer | na | Sequence sourced through https://www.tandfonline.com/doi/full/10.1080/19420862.2022.2123299 | E VQLLES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKG LEWVAVISY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KDMGWGSGWRP YYYYGMDV WGQG TTVTVS S | ELQ MT QSPSS LSA SVGD RVTITCR TSQS ISSYLNWY QQKPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQPEDSA TYYCQQS YDIPY T FGQGT KLEI K |
Adintrevimab | Whole mAb | G1 | Lambda | Phase-II/III | Active | EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSSISEDGYSTYYPDSLKGRFTISRDSAKNSLYLQMNSLRADDTAVYYCARDFSGHTAWAGTGFEYWGQGTLVTVSS | QSVLTQPPSVSGAPGQRITISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGSSSRNSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSVLYTFGTGTKVTVL | na | na | null | null | null | 2,021 | 2022 | SARS-CoV-2 Spike | Adagio Therapeutics | na | COVID-19 | na | na | null | E VQLVES GGG LV KPGG SLRLSC AASGF TFSSYYMNWVR QAPGKGL EWVSSI SEDGY STY YPDSLKG RFTISR DSAKN SLYLQMNSL RADDT AVYYCAR DFSGHT AW AGTG FEYW GQG TLVTVS S | QSVLTQPPSVSGAPGQ RITISCT GSSSNIGAG YDVHWYQ QLPGTAP KLLIYG SSSRNSGVPDRFSGSKSGTS AS LAI TGLQAEDEAD YYCQS YDSSL SVLYTF GTGT KVTV L |
Aducanumab | Whole mAb | G1 | Kappa | Approved | NFD | QVQLVESGGGVVQPGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWFDGTKKYYTDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDRGIGARRGPYYMDVWGKGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK | na | na | 6cnr:HL/6co3:HL | null | null | 2,013 | 2014 | APP | Biogen;Neurimmune | Alzheimer's disease | na | na | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF AFS SY GMHWVRQ APGKGL EWVAVIWF DGT KKYYTD SVKG RFTISR DNSKN TLYLQMNTL RAEDT AVYYCAR DRGIGARRGP YYMDVW GKG TTVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYCQ QSYSTP LTF GGG TKVEI K |
Afasevikumab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGGFGEFYWNFGLWGRGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK | na | na | 6ppg:HL:BA | null | null | 2,015 | 2016 | IL17A | NovImmune;Genentech | na | na | Autoimmune disorders;Inflammation | na | null | E VQLVES GGG LV QPGR SLRLSC AASGFT F DDY AMHWVR QAPGKGL EWVS G IN WSSGGI GY ADSVKG RFTISR DNAKNS LYLQMN SLRAEDT ALYYCAR DIGGFG EFYWNF G L WGRG TLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCR ASQS VRSY LA W Y QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWPPATFGGG TKVEI K |
Alacizumab | di-Fab | na | Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATITSGGSYTYYVDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCVRIGEDALDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDIAGSLNWLQQKPGKAIKRLIYATSSLDSGVPKRFSGSRSGSDYTLTISSLQPEDFATYYCLQYGSFPPTFGQGTKVEIK | na | na | null | null | null | 2,007 | 2008 | KDR | UCB | na | na | Non-small cell lung cancer | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSS YG MSWVRQ APGKG LEWVATIT SGGS YTYYVD SVKG RFTISR DNAKN TLYLQMN SLRAEDT AVYYCVRI GEDAL DYW GQ GTLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQD IAGSLNWLQ QKPGKA IKRLIYAT SSLDSGVPK R FSGSRSGSD YTLTISS LQPED F ATYYCLQ YGSFPPTFGQGT KVEI K |
Alemtuzumab | Whole mAb | G1 | Kappa | Approved | Active | QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIK | na | na | 1bey:HL/1ce1:HL | null | null | 2,000 | 2001 | CD52 | Bayer HealthCare Pharmaceuticals Inc.;Dana-Farber Cancer Institute;German CLL Study Group;Ohio State University Comprehensive Cancer Center;Sanofi;Sanofi Oncology;University of Cologne;University of Cambridge | Chronic lymphocytic leukaemia;Multiple sclerosis | Lymphoma;T-cell prolymphocytic leukaemia | Rheumatoid arthritis;Diffuse large B cell lymphoma;Graft-versus-host disease;Sezary syndrome;T-cell lymphoma | na | null | Q VQLQE SGPGL V RPSQ TLSLTCTV SG FTFTDFYMNWVR QPPGRGL EWIGFIR DKAKGY TTEY NPSVKG RVTMLVD TSKN QFSLRLSS VTAAD TAVYYCA REGHTAAPFDYWGQG SLVTVS S | DIQ M TQSPSS LSA SVGD RVTITCK ASQN IDKYLNWYQ QKPGKAP KLLIYN TNNLQTGVPSRFSGSGSGTD FTFTIS SLQ PEDIATYYCLQH ISRPRTFGQGT KVEI K |
Alirocumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFNNYAMNWVRQAPGKGLDWVSTISGSGGTTNYADSVKGRFIISRDSSKHTLYLQMNSLRAEDTAVYYCAKDSNWGNFDLWGRGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSVLYRSNNRNFLGWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTTPYTFGQGTKLEIK | na | na | null | null | null | 2,012 | 2013 | PCSK9 | Regeneron Pharmaceuticals;Sanofi;University Hospital Inselspital | Hypercholesterolaemia;Hyperlipoproteinaemia type IIa;Atherosclerosis;Dyslipidaemias | Coronary artery disease | na | VelocImmune Mouse | null | E VQLVES GGG LV QPGG SLRLSC AASGF TF NNY AMNWVR QAPGKGLD WVSTIS GSGGTTNYADSVKG RFIISR DSSKH TLYLQMN SLRAED TAVYYCA KDSNWGN FDL WGRG TLVTV SS | D IVMT QSPDS LAVS LGE RATINC KSSQ SVLYR SNNRN FLGWYQ QKPGQPPN LLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQQ YYTTPY T FGQGT KLEI K |
Alomfilimab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLVESGGGVVRPGGSLRLSCVASGVTFDDYGMSWVRQAPGKGLEWVSGINWNGGDTDYSDSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDFYGSGSYYHVPFDYWGQGILVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSRSYLAWYQQKRGQAPRLLIYGASSRATGIPDRFSGDGSGTDFTLSISRLEPEDFAVYYCHQYDMSPFTFGPGTKVDIK | na | na | 7joo:HL | null | null | 2,020 | 2021 | ICOS | Kymab | na | Gastic cancers;Non-small cell lung cancer;Melanoma;Hepatocellular carcinoma;Esophageal cancer;Head and neck squamous cell carcinoma | na | na | null | E VQLVES GG GVV RPGG SLRLSCVA SGV TF DDYGM SWVRQ APGKGL EWVSGIN WNGGDTDYSDSVK GRFTISR DNAKN SLYLQMN SLRAEDT ALYYCAR DFYGSGS YYHV PFDYWGQ GILVTV SS | E IVLTQ SPG TLSL SPGE RATLSCR ASQS VSRSYLAWYQQK RGQAP RLLIYG ASSRATGIPDRFSGDGSGT DFTLSIS RLE PEDF AVYYC H QYDMSPFTFGPGT KVD IK |
Alnuctamab | Bispecific mAb with Domain Crossover | G1;G1 | Kappa;Lambda | Phase-I | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSDNAMGWVRQAPGKGLEWVSAISGPGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVLGWFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSDEYLSWYQQKPGQAPRLLIHSASTRATGIPDRFSGSGSGTDFTLAISRLEPEDFAVYYCQQYGYPPDFTFGQGTKVEIK | EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS | QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL | None;None | None;None | None;None | 2,020 | 2021 | TNFRSF17;CD3E | Celgene Corporation | na | Multiple myeloma | na | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TF SDNAM GWVRQ APGKGL EWVSAI SGPGSS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAKVL G WF DYWGQG TLVTV SS | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS DEYLSWYQ QKPGQAP RLLIHS ASTRATGIPDRFSGSGSGTD FTLAIS RLE PEDFAVYYCQQY GYPPDF T FGQGT KVEI K |
Alsevalimab | Whole mAb | G1 | Kappa | Phase-I | Active | QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPSLRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNQFDPWGQGTLVTVSS | EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | VTCN1 | Five Prime Therapeutics | na | Solid tumours | na | na | null | QL QLQE SGPGL V KPSE TLSLTCTV SGGSIKSGS YYWGWIR QPPGKGL EWIGNIYYS GS TY YNPSLR SRVTISVD TSKN QFSLKLSS VTAADT AVYYCA REGSYPNQFDPWGQG TLVTVS S | E IVMT QSPA TLSV SPGE RATLSCR ASQSVSSN LAWYQ QKPGQAP RLLIYG ASTRATGIP ARFS GSGSGT EFTLTISS LQSED FAVYYC QQYHSFP FTF GGGT KVEI K |
Amatuximab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLQQSGPELEKPGASVKISCKASGYSFTGYTMNWVKQSHGKSLEWIGLITPYNGASSYNQKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDYWGSGTPVTVSS | DIELTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPGRFSGSGSGNSYSLTISSVEAEDDATYYCQQWSKHPLTFGSGTKVEIK | na | na | null | 4f33:BA:DC:FE:HG/4f3f:BA | null | 2,010 | 2011 | MSLN | Eisai Co Ltd;Morphotek;National Cancer Institute (USA) | na | Mesothelioma | Pancreatic cancer;Solid tumours | na | null | QV QLQ QSGPELEKPGA SVKISCK ASGY SFTGYTMNWVK QSHGKS LEWIGLIT PYNGASSYNQKFRG KATLTVD KSSST AYMDLLS LTSEDS AVYFCA RGGYDGRGF DY WGSGTP VTV SS | DI ELT QSP AIMS ASPGE KVTMTCS ASSS VSYMHWYQ QKSGTSPK RWIYD TSKLASGVPG RFS GSGSGN SYSLTISSVE AEDDA TYYCQQW SKHPL TF GSGT KVEI K |
Amivantamab | Bispecific mAb | G1;G1 | Kappa;Kappa | Approved | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS | AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK | QVQLVQSGAEVKKPGASVKVSCETSGYTFTSYGISWVRQAPGHGLEWMGWISAYNGYTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDLRGTNYFDYWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWFQHKPGKAPKLLIYAASSLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPITFGQGTRLEIK | None;6wvz:HL | None;None | None;None | 2,019 | 2020 | EGFR;MET | Genmab;Janssen Research & Development | Non-small cell lung cancer | Gastic cancer;Oesophageal cancer;Solid tumours | na | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSTYGMHWVRQ APGKG LEWVAVIW DDGS YKYY GDS VKGRFTISR DNSKN TLYLQMN SLRAED TAVYYCA RDG ITMVRGVM KDYFDYWGQG TLVTVS S | AI QLT QSPSS LSAS VGD RVTITCR ASQDIS SALVWYQ QKPGKAP KLLIYD ASSLESGVPSRFSGSESGTD FTLTIS SLQ PEDFATYYCQQ FNSYP LTF GGG TKVEI K |
Amlitelimab | Whole mAb | G4 | Kappa | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMNWVRQAPGKGLEWVSTISGSGGATRYADSVKGRFTISRDNSRNTVYLQMNSLRVEDTAVFYCTKDRLIMATVRGPYYYGMDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPNLLIYAASSLQSGVPSRFSGSGSETDFTLTISSLQPEDFATYYCQQSHSVSFTFGPGTKVDIK | na | na | null | null | null | 2,020 | 2021 | TNFSF4 | Kymab | na | Atopic dermatitis | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFS NY AMNWVR QAPGKG LEWVSTIS GSGGA TRY ADSVKG RFTISR DNSRN TVYLQMN S LRV ED TAVFYC TKDR LIMATVR GPY YYGMDV WGQG TTVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAPN LLIYAA SSLQSGVPSRFSGSGSET DFTLTIS SLQPE DFA TYYC QQSH SVSFTF GPGT KVDI K |
Amubarvimab | Whole mAb | G1 | Kappa | Phase-II/III | Active | EVQLVESGGGLVQPGGSLRLSCAASGITVSSNYMNWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYHCARDLVVYGMDVWGQGTTVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPTFGQGTKLEIK | na | na | 7cdi:HL | 7e8m:HL | null | 2,021 | 2022 | SARS-CoV-2 Spike RBD | Brii Biosciences | na | COVID-19 | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASG ITVS SNY MNWVR QAPGKGL EWVSLIY SGGS TYYA DSVKG RFTISR DNSKN TLYLQMNS LRAEDT AVYHC ARD LVVYGMDV WGQG TTVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QYGSSPTFGQGT KLEI K |
Anbenitamab | Bispecific mAb | G1;G1 | Kappa;Kappa | Phase-II/III | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK | EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK | None;1fvc:DC:BA/1n8z:BA/4hkz:BA/4ub0:HL/5xhg:BA:DC/5xhf:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/6mh2:AB:CD/6oge:ED/7mn8:DC | None;1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC | None;5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL | 2,020 | 2021 | ERBB2 (Domain II);ERBB2 (Domain IV) | Alphamab | na | Breast cancer;Gastric cancer | na | na | 4llu is 94.7% identical to ERBB2 (domain II) Fv | E VQLVES GGG LV QPGG SLRLSC AASGF TFT DY TMDWVR QAPGKG LEWVADV NPNSGGS IY NQRFKG RFTLSVD RSKN TLYLQMNS LRAEDT AVYYCA RNLGPS FYFDY WGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQD VNTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSRSGTD FTLTIS SLQP EDFAT YYCQ QHYTTPPTFGQGT KVEI K |
Andecaliximab | Whole mAb | G4 | Kappa | Phase-III | Discontinued | QVQLQESGPGLVKPSETLSLTCTVSGFSLLSYGVHWVRQPPGKGLEWLGVIWTGGTTNYNSALMSRFTISKDDSKNTVYLKMNSLKTEDTAIYYCARYYYGMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDVRNTVAWYQQKPGKAPKLLIYSSSYRNTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYITPYTFGGGTKVEIK | na | na | 5th9:HL:IM:JN | null | null | 2,016 | 2017 | MMP9 | Gilead Sciences | na | na | Chronic obstructive pulmonary disease;Crohn's disease;Cystic fibrosis;Rheumatoid arthritis;Ulcerative colitis;Gastric cancer;Solid tumours;Glioblastoma | na | null | QV QLQE SGPGL V KPSE TLSLTCTV SGF SLLSYGVHWVR QPPGKGL EWLGVIWT GGTTNYNSA LMSRFTIS KDDSKN TVYLKM NSLKTEDT AIYYCARYY YGMDYWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCK ASQD VRNT VAWYQ QKPGKAP KLLIYS SSYRNTGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC Q QHYITP YT FGGGT KVEI K |
Anetumab | Whole mAb ADC | G1 | Lambda | Phase-II | Active | QVELVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQAPGKGLEWMGIIDPGDSRTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGQLYGGTYMDGWGQGTLVTVSS | DIALTQPASVSGSPGQSITISCTGTSSDIGGYNSVSWYQQHPGKAPKLMIYGVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYDIESATPVFGGGTKLTVL | na | na | null | null | null | 2,013 | 2014 | MSLN | Bayer HealthCare;ImmunoGen;MorphoSys;National Cancer Institute (USA) | na | Lung cancer;Mesothelioma;Ovarian cancer;Pancreatic cancer;Solid tumours;Non-small cell lung cancer;Malignant thymoma | Fallopian tube cancer;Peritoneal cancer | MorphoSys HuCAL Phage Display | null | Q VELVQ SGA EVK KPGE SLKISC KGSGY SFTSYWIGWVR QAPGKG LEWMGII DPGDSRT RY SPSFQG QVTIS ADKS ISTAYLQWS SLKASDT AMYYC ARGQ LY GG TY MDGWGQG TLVTVS S | DI ALT QPA SV SGSPGQ SITISCT GTSSDIGGY NSVSWYQ QHPGKAP KLMIYGV NNRPSGVSNRFSGSKSGN TASLTIS GLQAEDEAD YYCSSY DIESATP V FGGGT KLTV L |
Anifrolumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLESMGIIYPGDSDIRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAWYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLTITRLEPEDFAVYYCQQYDSSAITFGQGTRLEIK | na | na | 4qxg:HL | null | null | 2,013 | 2014 | IFNAR1 | Medarex;Medical University of Vienna;MedImmune | Systemic lupus erythematosus | Lupus nephritis | Rheumatoid arthritis;Scleroderma | Medarex UltiMAb Mouse | null | E VQLVQ SGA EVK KPGE SLKISC KGSG YIFT N YWIAWVR QMPGKGLE SMGII YPGDSD IRY SPSFQG QVTIS ADKS ITTAYLQWS SLKASDT AMYYCAR HDIEGFDYWGRG TLVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSSS FFAWYQ QKPGQAP RLLIYG ASSRATGIPDRLSGSGSGT DFTLTITR LEPED FAVYYCQ QYDSSA ITF GQGT RLEI K |
Anivovetmab | Canine Whole mAb | G2 | Kappa | Unknown | Active | QVQLKESGPGLVAPSQTLSLTCTVSGFSLSSYHVHWVRQPPGKGLEWLGVMWNDGDTSYNLALNSRLSISRDTSKSQVFFKMSSLQTEDTATYYCARPELPGLTYGVWFPYWGQGTLVTVSA | DIVMTQTPASMSISVGDRVTMNCKASQNVDSNVDWYQQKTGQSPNLLIYKASNRNTGVPDRFTGSGSGTDFTFTISNMQAEDLAVYYCMQSTSYPLTFGSGTKLEIK | na | na | null | null | 3iy6:BA/3jcx:HL | 2,022 | na | VP2 (Canine) | TBC | TBC | TBC | TBC | TBC | null | Q VQLKE SGPGL V APSQ TLSLTCTV SGF S LS SYHVHWVR QPPGKGL EWLGVMW NDGDTS YNLAL NS RLSIS RDTSKS QVFFKM SSLQTEDT ATYYCA RPELPGL TYGVWF PYWGQG TLVTVS A | D IVMT QTPA SMSIS VGD RVTMNCK ASQNVDSNV DWYQQ KTGQSPN LLIYKA SNRNTGVPDRFTGSGSGT DFTFTIS NMQAED LAVYYCM QSTSYP LTF GSGT KLEI K |
Anrukinzumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFISYAMSWVRQAPGKGLEWVASISSGGNTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLDGYYFGFAYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASESVDNYGKSLMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPWTFGGGTKVEIK | na | na | null | null | null | 2,007 | 2008 | IL13 | Pfizer;Wyeth | na | na | Asthma;Ulcerative colitis | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFISYAMSWVR QAPGKG LEWVASIS SGGNT Y YPDSVK GRFTIS RDNAKN SLYLQMNS LRAEDT AVYYCARL DG YYFGFAYW GQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCK ASESVD NYGKSLMHWYQ QKPGKAP KLLIYRA SNLESGVPSRFSGSGSGTD FTLTIS SLQP EDFA TYYCQ QSNEDPWTFGGG TKVEI K |
Anselamimab | Whole mAb | G1 | Kappa | Phase-III | Active | QVQLKESGPGLVAPSQSLSITCTVSGFSLSSYGVSWVRQPPGKGLEWLGVIWGDGSTNYHPNLMSRLSISKDISKSQVLFKLNSLQTDDTATYYCVTLDYWGQGTSVTVSS | DVVMTQTPLSLPVSLGDQASISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGLYFCFQTTYVPNTFGGGTKLEIK | na | na | null | null | null | 2,021 | 2022 | Light Chain Amyloid Fibrils | Caelum Biosciences | na | AA amyloidosis | na | na | Oct '22: Amended target. Targets a conserved epitope across light chain amyloid fibrils: Am J Pathol. 2000;157(4):1239–46;Clin Cancer Res. 2003;9(10):3831S-3838S;Biochemistry. 2007;46(5):1240–7. | Q VQLKE SGPGL V APSQ SLSITCTV SG FSL S SYGVSWVR QPPGKGL EWLGVIW GDGSTNYHPNLMS RLSI SKDISKS QVLFKLNS LQTDDTA TYYCVTLD YWGQG TSVTVS S | DV VMT QTPLSLPVSLGDQ ASISC RSSQ SLVHR NGN TYLHWYLQ KPGQSP KLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDL GLYFCFQTTY VPNTFGGG TKLEI K |
Ansuvimab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLIQPGGSLRLSCAASGFALRMYDMHWVRQTIDKRLEWVSAVGPSGDTTYADSVKGRFAVSRENAKNSLSLQMNSLTAGDTAIYYCVRSDRGVAGLFDSWGQGILVTVSS | DIQMTQSPSSLSASVGDRITITCRASQAFDNYVAWYQQRPGKVPKLLISAASALHAGVPSRFSGSGSGTHFTLTISSLQPEDVATYYCQNYNSAPLTFGGGTKVEIK | na | na | null | 5fha:HL/5fhc:HL | null | 2,020 | 2021 | Zaire Ebolavirus GP1 | Ridgeback Biotherapeutics | Zaire ebolavirus infection | na | na | na | null | E VQLVES GGG LI QPGG SLRLSC AASGF ALRMY DM HW V R QT IDKR LEWVSAV GPSGDTT YA DSVKG RFAVS R ENAKNS LSLQM N S LTAGDT AIYYCVR SDRGV AGLF DSWGQ GILVTVS S | DIQ MT QSPSS LSA SVGD RITITCR AS Q A FDNYVAWYQ QRPGKVP KLLISA A SA LHAGVPS R FSGSGSGT HFTLTIS SLQP EDVAT YYC QNYNSAP LTF GGG TKVEI K |
Anumigilimab | Whole mAb | G4 | Kappa | Phase-I | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSLYWMGWVRQAPGKGLEWVSSISSSGGVTPYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLGELGWFDPWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGISSYLNWYQQKPGKAPKLLIYYASNLQNGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK | na | na | null | null | null | 2,021 | 2022 | CSF3R | CSL Behring | na | Inflammatory diseases;Hidradenitis suppurativa;Localised pustular psoriasis | na | na | null | E VQLLES GGG LV QPGG SLRLSCA ASGF TFSLYWMGWVR QAPGKG LEWVSSIS SSGGVTPYADSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAK LGELGW F DPWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQGI SSYLNWY QQKPGKAP KLLIYYA SNLQNGVPS RF SGSGSGTD FTLTIS SLQPE DFA TYYCQ QSYSTP LTF GGG TKVEI K |
Anvatabart | Whole mAb ADC | G1 | Kappa | TBC | Active | EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK | na | na | 1fvc:DC:BA/4hkz:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED/7mn8:DC | 1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC | 5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL | 2,022 | na | ERBB2 | TBC | TBC | TBC | TBC | Humanised | Anvatabart has an identical V domain to Coprelotamab, Cinrebafusp, Timigutuzumab, and Trastuzumab | E VQLVES GGG LV QPGG SLRLSCA ASGFNIKD TYIHWVRQ APGKG LEWVARIY PTNGY TRYA DSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCS RWGGDG FYAMD YWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQD VNTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSRSGTD FTLTIS SLQP EDFAT YYCQ QHYTTPPTFGQGT KVEI K |
Anzurstobart | Whole mAb | G1 | Kappa | Phase-I | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFRGYGISWVRQAPGQGLEWMGWISAYGGETNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREAGSSWYDFDLWGRGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGASFPITFGGGTKVEIK | na | na | null | null | null | 2,022 | na | SIRPα | Celgene Corporation | na | Acute myeloid leukaemia;Myelodysplastic syndromes | Non-Hodgkin's lymphoma;Solid tumours | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFRGYGISWVRQ APGQGL EWMGWISA YGGETNY AQKL QG RVTMTT DTSTS TAYMELRSL RSDDT AVYYCAR EAGSS WYDFDL WGRG TLVTV SS | DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWY QQKPGKAP KLLIYAA SNLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYC QQGASF PITF GGG TKVEI K |
Apamistamab | Whole mAb Radiolabelled | G1 | Kappa | Phase-III | Active | EVKLLESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPTSSTINFTPSLKDKVFISRDNAKNTLYLQMSKVRSEDTALYYCARGNYYRYGDAMDYWGQGTSVTVSS | DIALTQSPASLAVSLGQRATISCRASKSVSTSGYSYLHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPFTFGSGTKLEIK | na | na | null | null | null | 2,018 | 2019 | PTPRC | Actinium Pharmaceuticals;Fred Hutchinson Cancer Research Center | na | Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma | Hodgkin's disease;Non-Hodgkin's lymphoma | na | null | E VKLLES GGG LV QPGG SLKLSCA ASGFDFSR YWMSWVR QAPGKGL EWIGEI NPTSS TINF TPSLKD KVFISR DNAKN TLYLQMSKV RSEDT ALYYC ARGN YYRY GDAMDYWGQG TSVTVS S | DI ALT QSPA SLAVS LGQ RATISCRA SKSVSTSGY SYLHWYQ QKPGQPP KLLIYLA SNLESGVP ARFS GSGSGTD FTLNIHP VEEEDA A TYYC QHSRELP FT FGSGT KLEI K |
Apitegromab | Whole mAb | G4 | Lambda | Phase-III | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLLVRFLEWSHYYGMDVWGQGTTVTVSS | QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVHWYQQLPGTAPKLLIYSDNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGVFGGGTKLTVL | na | na | null | null | 6umx:HL:hl | 2,020 | 2021 | pro-GDF-8 | Scholar Rock | na | Spinal muscular atrophy;Muscular atrophy;Spinal cord injuries | na | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKG LEWVAVISY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYC ARDLLVRFLEWSHY YGMD V WGQG TTVTVS S | QSVLTQPPSASGTPGQ RVTISC SGSSSNIGSN TVHWYQQ LPGTAP KLLIY SDNQRPSGVPDRFSGSKSGTS ASL A I SGLQSEDEAD YYCAAW DDSLNGVFGGGT KLTV L |
Aprutumab | Whole mAb ADC | G1 | Lambda | Phase-I | Discontinued | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGTSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVRYNWNHGDWFDPWGQGTLVTVSS | QSVLTQPPSASGTPGQRVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYENYNRPAGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSSWDDSLNYWVFGGGTKLTVL | na | na | null | null | null | 2,016 | 2017 | FGFR2 | Bayer | na | na | Solid tumours | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSAI SGSGT STYYA DSVKG RFTISR DNSKN TLYLQMNS LRAEDT AVYYCARVRYN WNHGDWFDPWGQ GTLVTVS S | QSVLTQPPSASGTPGQ RVTISC SGSSSNIGNN YVSWYQQ LPGTAP KLLIYE NYNRPAGVPDRFSGSKSGT SASLAI SGLRSEDEAD YYC SSWDDSLN YWVF GGGT KLTV L |
Arcitumomab | Whole mAb | G1 | Kappa | Approved (w) | NFD | EVKLVESGGGLVQPGGSLRLSCATSGFTFTDYYMNWVRQPPGKALEWLGFIGNKANGYTTEYSASVKGRFTISRDKSQSILYLQMNTLRAEDSATYYCTRDRGLRFYFDYWGQGTTLTVSS | QTVLSQSPAILSASPGEKVTMTCRASSSVTYIHWYQQKPGSSPKSWIYATSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQHWSSKPPTFGGGTKLEIK | na | na | 1clo:HL | null | null | 1,995 | 1996 | CEA | Immunomedics;Giliad Sciences | Colorectal cancer | na | na | na | null | E VKLVES GGG LV QPGG SLRLSC ATSGF TFTDYYMNWVR QPPGKA LEWLGFIG NKANGY TTEYSASVKGRFTIS RDKSQ SILYLQMNTL RAEDS ATYYCT RDRG LRFYFDY WGQG TTLTVS S | QT VL SQSP AILS ASPGE KVTMTCR ASSS VTYIHWYQ QKPGSSPK SWIYAT SNLASGVP ARFS GSGSGT SYSLTISRVE AEDA ATYYCQH WSSKPPTFGGGT KLEI K |
Ascrinvacumab | Whole mAb | G2 | Kappa | Phase-II | Discontinued | QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGEYYWNWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARESVAGFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGTSSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGQGTRLEIK | na | na | null | null | null | 2,015 | 2016 | ACVRL1 | Duke University Medical Center;Fondazione IRCCS Istituto Nazionale dei Tumori;Pfizer;Suzhou Kintor Pharmaceuticals | na | na | Colorectal cancer;Liver cancer;Solid tumours;Urogenital cancer;Age-related macular degeneration;Cancer;Liver Cancer | na | null | QV QLQE SGPGLVKPSQ TLSLTCTV SGGSISSG EYY WNWIR QHPGKGL EWIGYIYYS GST Y YNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCA RESVAG FDY WGQG TLVTV SS | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS SSY LAWYQ QKPGQAP RLLIYG TSSRATGIPDRFSGSGSGT DFTLTISR LE PEDFA VYY CQQ YGSSP ITF GQGT RLEI K |
Aselizumab | Whole mAb | G4 | Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAPGKGLEWVASISTGGSTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARDYDGYFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPWTFGQGTKVEIK | na | na | null | null | null | 2,003 | 2003 | L-Selectin | PDL Biopharma | na | na | Adult respiratory distress syndrome;Crohn's disease;Psoriasis;Reperfusion injury;Shock | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSTYAMSWVR QAPGKG LEWVASIS TGGST Y YPDSVK GRFTISR DNAKN TLYLQMNS LRAEDT AVYYCAR DYDGY FDY WGQG TLVTV SS | DI QMT QSPSS LSA SVGD RVTITCK ASQS V DYDGD SYMNWYQ QKPGKAP KLLIYAA SNLESGIPSRFSGSGSGTD FTLTISS LQPED F ATYYCQ QSNEDPWTFGQGT KVEI K |
Astegolimab | Whole mAb | G2 | Kappa | Phase-II | Active | EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIYPGNSDTRFSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHGTSSDYYGLDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQDDNFPLTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | IL1RL1 | Amgen;Genentech;University of Leicester | na | Allergic asthma;Atopic dermatitis;Chronic obstructive pulmonary disease | Asthma;Rhinosinusitis | na | null | E VQLVQ SGA EVK KPGE SLKISC KGSGYS F T NYWIGWVRQ MPGKGL EWMGIIY PGNSDTRFSPSFQG QVTIS ADKS ITTAYLQWS SLKASDT AMYYCA RHGTSSDY YGLDVW GQG TTVTVS S | DIQMTQSPSS LSA SVGD RVTITCQ ASQD ISNYLNWYQ QKPGKAP KLLIYD ASNLETGVPSRFSGSGSGTD FTFTIS SLQ PEDIATY YC QQDDNFP LTF GGG TKVEI K |
Atezolizumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK | na | na | 5x8l:FK:HM:GL:JO:SN | 5xxy:HL | null | 2,014 | 2015 | CD274 | Amgen;ARCAGY/GINECO Group;BioLineRx;Chugai Pharmaceutical;Clovis Oncology;Dana-Farber Cancer Institute;Duke University;European Organisation for Research and Treatment of Cancer;Exelixis;Fondazione Michelangelo;GEICO (Spanish Ovarian Cancer Research Group);Genentech;GERCOR;Gradalis;H. Lee Moffitt Cancer Center and Research Institute;Immune Design;Incyte Corporation;Johns Hopkins University;Kaiser Permanente;M. D. Anderson Cancer Center;Memorial Sloan-Kettering Cancer Center;National Cancer Center (Korea);National Cancer Institute (USA);Netherlands Cancer Institute;Roche;Sanofi;Seattle Genetics;University Hospital Southampton NHS Foundation Trust;University Medical Center Groningen;University of California;University of California at San Francisco;University of Oklahoma;Yale University | Non-small cell lung cancer;Urogenital cancer;Breast cancer;Small cell lung cancer | Bladder cancer;Cervical cancer;Colorectal cancer;Fallopian tube cancer;Head and neck cancer;Liver cancer;Malignant melanoma;Ovarian cancer;Peritoneal cancer;Prostate cancer;Renal cell carcinoma;Anal cancer;Brain metastases;Chronic lymphocytic leukaemia;Cutaneous T-cell lymphoma;Diffuse large B cell lymphoma;Endometrial cancer;Gastric cancer;Gynaecological cancer;Mantle-cell lymphoma;Marginal zone B-cell lymphoma;Oesophageal cancer;Soft tissue sarcoma;Solid tumours;Thyroid cancer;Waldenstrom's macroglobulinaemia;Acute myeloid leukaemia;Follicular lymphoma;Glioblastoma;Pancreatic cancer;Haematological malignancies;Multiple myeloma;Non-Hodgkin's lymphoma | Hodgkin's disease;Myelodysplastic syndromes | Human Phage Display | null | E VQLVES GGG LV QPGG SLRLSC AASGF TF SDS WIHWVRQ APGKG LEWVAWI SPYGGS TYYAD SVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCAR RHWPGGFD Y WGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQD VSTA VAWY Q QKPGKAP KLLIYSASFLY SGVPSRFSGSGSGTD FTLTIS SLQ PEDFAT YYCQQYLY HPATFGQGT KVEI K |
Atibuclimab | Whole mAb | G4 | Kappa | Phase-II | Active | DVQLQQSGPGLVKPSQSLSLTCTVTGYSITSDSAWNWIRQFPGNRLEWMGYISYSGSTSYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCVRGLRFAYWGQGTLVTVSS | DIVLTQSPASLAVSLGQRATISCRASESVDSYVNSFLHWYQQKPGQPPKLLIYRASNLQSGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPYTFGGGTKLEIK | na | na | null | null | null | 2,020 | 2021 | CD14 | ICOS Corporation;Implicit Bioscience | na | Acute lung injury;COVID-19 | Adult respiratory distress syndrome;Motor neuron disease;Septic shock | na | null | DV QLQQ SGPGLVKPSQ SLSLTCTVT G YSI TSDS AWNWIR QFPGNR LEWMGYISY SGSTSYNPSLK SRISITR DTSKN QFFLQLN S V TTEDTA TYYCVR G LRFAYW GQG TLVTVS S | D IVLT QSPA SLAVS LGQ RATISCR ASES VDSYVNSFLHWYQ QKPGQPP KLLIYRA SNLQSGIPA RF SGSGSRT DFTLTI NPVEADD V ATYYCQ QSNEDPYTFGGGT KLEI K |
Atidortoxumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLQESGPGLVRPSETLSLTCAVSGYSISSGMGWGWIRQPPGKGLEWIGSIDQRGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDAGHAVDMDVWGKGTTVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYVFPLTFGGGTKVEIK | na | na | null | null | null | 2,017 | 2018 | Toxin A | Adimab;Arsanis;X4 Pharmaceuticals | na | na | Staphylococcal infections | na | null | E VQLQ ESGPG LV RPSE TLSLTCAV SGY SI SSGMG WGWIR QPPGKGL EWIGSI DQRGS TYY NPSLKS RVTISVD TSKN QFSLKLSS VTAADT AVYYCA RDAGH AVDMDV WGKG TTVTVS S | DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISRWLAWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATY YC QQGY VFPLTF GGG TKVEI K |
Atinumab | Whole mAb | G4 | Kappa | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMSWVRQAPGKGLEWVATIKQDGSQKNYVDSVKGRFTISRDNAKNSLYLRLNSLRAEDTAVYYCATELFDLWGRGSLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTKLEIK | na | na | null | null | null | 2,010 | 2011 | RTN4 | Novartis | na | na | Spinal cord injuries | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TF SN YWMSWVR QAPGKG LEWVATIK QDGSQK NYVD SVKG RFTISR DNAKN SLYLRLN SLRAEDT AVYYCA TEL F DLWGRGS LVTV SS | E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPE D FAVYYCQ QRSNWP ITF GQGT KLEI K |
Atisnolerbart | Whole mAb | G4 | Kappa | TBC | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFISYNIFWVRQATGQGLDWMGWMNPFRNNAGYAQKFQGRVTVTWDTSISTAYMELSSLSSEDTAIYYCAREHGSSWGFFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK | na | na | 7mxl:JK/7n0v:HL | null | null | 2,022 | na | Bet v 1 | Regeneron | TBC | TBC | TBC | na | Antigen: Bet v 1 (Betula alleghaniensis (yellow birch) pollen allergen 1. Also known as REGN5715. Identical V region sequence to Bremzalerbart. | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFISYNIFWVR QATGQGLD WMGW MNPFRNNAGY AQKF QG RVTVTW DTSI STAYMELS SLSSEDT AIYYCAR EHGSSW GFFD YWGQG TLVTV SS | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYC Q QYGSSPWTFGQGT KVEI K |
Atoltivimab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | QVQLVESGGGVVQPGRSLRLSCAASGFTFNNYGMHWVRQAPGMGLEWVAVIWHDGSDKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARNWNLFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRITITCRASQSISTYLHWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSTPPINFGQGTKLEIK | na | na | null | null | null | 2,018 | 2019 | Zaire Ebolavirus GP | Regeneron Pharmaceuticals | na | na | Ebola virus infections | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TF NNY GMHWVRQ APGMG LEWVAVIWH DGSDK YYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RNWN LF DYWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RITITCR ASQS ISTYLHWY QQKPGKAP KLLIYAA STLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYCQ QSFSTPPINFGQGT KLEI K |
Avdoralimab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMHWVRQATGKGLEWVSAIDTGGGTYYADSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDYYYYASGSYYKAFDIWGQGTMVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSPLTFGQGTKLEIK | na | na | null | null | null | 2,019 | 2020 | C5AR1 | Novo Nordisk;Innate Pharma | na | Bullous pemphigoid;COVID-19;Urticaria;Liver cancer;Non-small cell lung cancer;Solid tumours | Rheumatoid arthritis | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYVMHWVR Q ATGKGL EWVSAID TGGG TYYA DSVKG RFTIS RE NAKNS LYLQMNS LRAGD TAVYYCA RD YYYY ASGS YYKAFDI WGQG TMVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS SR YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LE PEDFA VYY CQQ YGSPL T FGQGT KLEI K |
Avelumab | Whole mAb | G1 | Lambda | Approved | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS | QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL | na | na | 4nki:HL/5grj:HL | null | null | 2,015 | 2016 | CD274 | AIO Studien gGmbH;Array BioPharma;Chong Kun Dang;Dana-Farber Cancer Institute;Debiopharm;eFFECTOR Therapeutics;EMD Serono;Forty Seven;Fred Hutchinson Cancer Research Center;Gachon University Gil Medical Center;Hellenic Cooperative Oncology Group;Hospices Civils de Lyon;Johannes Gutenberg-University Mainz;M. D. Anderson Cancer Center;Merck KGaA;National Cancer Institute (USA);National Cancer Institute Slovakia;Netherlands Cancer Institute;Pfizer;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syndax Pharmaceuticals;Transgene;University College London;University of Birmingham;University of California San Diego;University of Iowa;Vaccinex;Vanderbilt-Ingram Cancer Center;VAXIMM;Verastem Oncology;Washington University School of Medicine | Merkel cell carcinoma;Urogenital cancer;Renal cell carcinoma | Breast cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Bladder cancer;Endometrial cancer;Fallopian tube cancer;Germ cell and embryonal neoplasms;Gestational trophoblastic disease;Glioblastoma;Haemangiosarcoma;Intestinal cancer;Leiomyosarcoma;Nasopharyngeal cancer;Neuroendocrine tumours;Osteosarcoma;Peripheral T-cell lymphoma;Peritoneal cancer;Prostate cancer;Recurrent respiratory papillomatosis;Small cell lung cancer;Solid tumours;Squamous cell cancer;Thymoma;Liposarcoma;Lymphoma;Oropharyngeal cancer;Pancreatic cancer;Acute myeloid leukaemia;Follicular lymphoma;Hodgkin's disease;Liver cancer;Meningioma;Bone metastases;Anal cancer;Cervical cancer;Vulvovaginal cancer;Meningioma | na | Human Phage Display | Avelumab and Bintrafusp have identical V domains | E VQLLES GGG LV QPGG SLRLSCA ASGF TFSSYIMMWVRQ APGKG LEWVSSI YPSGG ITFYAD TVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCARIK LGT VTTVDY WGQG TLVTVS S | QSALTQPA SV SGSPGQ SITISCT GTSSDVGG YNYVSWYQ QHPGKAP KLMIYD VSNRPSGVSNRFSGSKSGN TASLTIS GLQAEDEAD YYCSS YTSSST RVF GTGT KVTV L |
Avizakimab | Whole mAb | G1 | Kappa | Phase-I/II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYWMHWVRQAPGQGLEWMGTIDPSDQYTIYSQNFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYGFAMDYWGQGTLVTVSS | DIQLTQSPSSLSASVGDRVTITCRASQDISNFLNWYQQKPGKAVKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGHTLPRTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | IL21 | MedImmune;Boston Pharmaceuticals | na | Systemic lupus erythematosus | Autoimmune disorders | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTDYWMHWVR QAPGQG LEWMGTI DPSDQ YTIYSQ NFKG RVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RYGF AMD YWGQG TLVTVS S | DI QLT QSPSS LSA SVGD RVTITCR ASQD ISNFLNWYQ QKPGK AVKLLIYYT SRLHSGVPS R FSGSGSGTD YTLTIS SLQ PEDFATY Y C QQGHTLPRTFGGGT KVEI K |
Axatilimab | Whole mAb | G4 | Kappa | Phase-II | Active | EVTLKESGPALVKPTQTLTLTCTFSGFSLTTYGMGVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIGPIKYPTAPYRYFDFWGQGTMVTVSS | DIQMTQSPSSLSASVGDRVTITCLASEDIYDNLAWYQQKPGKAPKLLIYYASSLQDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQDSEYPWTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | CSF1R | Syndax Pharmaceuticals;AstraZeneca;UCB | na | Cholangiocarcinoma;Graft-versus-host disease;COVID-19 | Solid tumours | na | null | E VTLKE SGPA LV KPTQ TLTLTCTF SGF SLTTYGMGVGWIR QPPGKA LEW LANIW WDDDKYYNPSLKN RLTIS KDTSKN QVVLTMT NMDPVDTA TYYCARI GPIKYPTAPY RYFDF WGQG TMVTVS S | DIQMTQSPSS LSA SVGD RVTITCL ASED IYDNLAWYQ QKPGKAP KLLIYYA SSLQDGVPS RF SGSGSGTD YTLTIS SLQPEDF ATYYCL QDSEYPW T FGGG TKVEI K |
Azintuxizumab | Whole mAb ADC | G1 | Kappa | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMAWVRQAPGKGLEWVASINYDGSSTYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRGYYFDYWGQGTTVTVSS | DVVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPPFTFGGGTKVEIK | na | na | null | null | null | 2,016 | 2017 | SLAMF7 | AbbVie | na | na | Multiple myeloma | na | null | E VQLVES GGG LV QPGG SLRLSCA ASGF TF SD YYMAWVRQ APGKG LEWVASIN YDGS STYYVD SVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCA RDRG YYFDY WGQG TTVTVS S | DV VMT QTP LSLSV TPGQP ASISCR SSQ SLVH SNGN TYLHWYLQ KPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AED VGVYFCS QSTHVPPF T FGGG TKVEI K |
Bafisontamab | Bispecific Mixed mAb and Fab | G1;na | Kappa;Kappa | Phase-I/II | Active | QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS | DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGFSWVRQAPGQGLEWMGWISASNGNTYYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVYADYADYWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGINTWLAWYQQKPGKAPKLLIYAASSLKSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGGGTKVEIK | 5sx4:HL:JI/5sx5:JK:HL;None | None;None | None;None | 2,021 | 2022 | EGFR;MET | EpimAb Biotherapeutics | na | Non-small cell lung cancer;Solid tumours | na | na | Fv1 is Panitumumab | Q VQLQE SGPGL V KPSE TLSLTCTVS GGSVSSGD YYWTWIRQ SPGKGL EWIGHIYYS GNTNYNPSLK SRLTISID TSKT QFSLKLSS VTAADT AIYYCVR DRVTG AFDIW GQG TMVTVS S | DIQMTQSPSS LSA SVGD RVTITCQ AS QDISNYLNWYQ QKPGKAP KLLIYD ASNLETGVPSRFSGSGSGTD FTFTIS SLQ PEDIATYFCQH FDHLP LAF GGGT KVEI K |
Balstilimab | Whole mAb | G4 | Kappa | Phase-III | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASNGDHWGQGTLVTVSS | EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPRTFGQGTKVEIK | na | na | null | null | null | 2,018 | 2019 | PDCD1 | Agenus;Ludwig Institute for Cancer Research | na | Cervial cancer;Solid tumours;Colorectal cancer;Haemangiosarcoma;Soft tissue sarcoma | na | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAVIWY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCA SNGDHWGQ GTLVTVS S | E IVMT QSPA TLSV SPGE RATLSCR ASQSVSSN LAWYQ QKPGQAP RLLIYG ASTRATGIP ARFS GSGSGT EFTLTISS LQSED FAVYYCQQ YNNWPRTFGQGT KVEI K |
Bamlanivimab | Whole mAb | G1 | Kappa | Approved | Active | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGYYEARHYYYYYAMDVWGQGTAVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLSWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTITSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK | na | na | 7l3n:DE/7kmg:AB:DE | null | null | 2,020 | 2021 | SARS-CoV-2 Spike | Abcellera;Eli Lilly and Company;National Institute of Allergy and Infectious Diseases | COVID-19 | na | na | Baiting from convalescent human B-cells | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT F S NYAISWVR QAPGQGL EWMGRIIPILG IANYAQK FQG RVTITA DKSTS TAYMELS SLRSEDT AVYYCA RG YY EAR HYYYYYAMD VWGQG TAVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLSWY QQKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTITS LQP EDFA TYYCQ QSYSTPRTFGQGT KVEI K |
Bapineuzumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRYDHYSGSSDYWGQGTLVTVSS | DVVMTQSPLSLPVTPGEPASISCKSSQSLLDSDGKTYLNWLLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPRTFGQGTKVEIK | na | na | null | null | 4ojf:HL/4hix:HL | 2,005 | 2006 | APP | JANSSEN Alzheimer Immunotherapy;Pfizer;Wyeth;Elan Corporation | na | na | Alzheimer's disease | na | Jain paper: "Conflicting literature sequences in FR3 of VH - AKNTLYLQMNSLRAEDTAV vs. AKNSLYLQMNSLRAEDTAL" | E VQLLES GGG LV QPGG SLRLSC AASGF TFS NYG MSWVRQ APGKG LEWVASIR SGGGR TYYS DNVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCVRYD HYSGSSDYWGQ GTLVTVS S | DV VMT QSPLSLPVTPGEPA SISC KSSQ SLL DSDGK TYLNWLL QKPGQSPQ RLIYLVSK LDSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCW QGTHFPRTFGQGT KVEI K |
Bapotulimab | Whole mAb | G2 | Kappa | Phase-I | Active | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGRLPYGDFWDSWGQGTLVTVSS | DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKLEIR | na | na | null | null | null | 2,020 | 2021 | ILDR2 | Bayer | na | Solid tumours | na | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWM GG IIPILGI A N YAQ KFQG RVTITA DKSTS TAYMELS SLRSEDT AVYYCA RGRLPYGDFWDSWGQG TLVTV SS | DI VMT QSPLSLPVTPGEPA SISC RSSQ SLLY SNGYN YLDWYL QKPGQSP QLLIYL GSNRASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCMQA LQTPL TF GGGT KLEI R |
Barecetamab | Whole mAb | G1 | Lambda | Phase-I | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYDMSWVRQAPGKGLEWVSTIDLDSGSIYYADSVQGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDLHMGPEGPFDYWGQGTLVTVSS | QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNSVSWYQQLPGTAPKLLIYSDNHRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQGWDTSLSGHVFGGGTKLTVL | na | na | 7d85:BC:EF | null | null | 2,020 | 2021 | ERBB3 | ISU Abxis | na | Head and neck cancer | Solid tumours | Antibody Phage Display | null | E VQLLES GGG LV QPGG SLRLSC AASGF TF SDYDM SWVR QAPGKGL EWVSTID LDSG SIYYAD SVQG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KDLHMGPEGPFDYWGQG TLVTVS S | QSVLTQPPSASGTPGQ RVTISC SGSSSNIGSNS VS WYQ QLPGTAP KLLIY SDNHRPSGVPDRFSGSKSGT SASLAI SGLRSED E A DY YC QGWDTSLSG HVF GGGT KLTV L |
Barzolvolimab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGASVKLSCKASGYTFTDYYINWVRQAPGKGLEWIARIYPGSGNTYYNEKFKGRATLTADKSTSTAYMQLSSLRSEDTAVYFCARGVYYFDYWGQGTTVTVSS | DIVMTQSPSSLSASVGDRVTITCKASQNVRTNVAWYQQKPGKAPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISSLQPEDFADYFCQQYNSYPRTFGGGTKVEIK | na | na | null | null | null | 2,021 | 2022 | KIT | Celldex Therapeutics | na | Chronic idiopathic urticaria | na | na | null | Q VQLVQ SGA EVK KPGA SVKLSCK ASGY TFTDYYINWVR QAPGKG LEWIARI YPGSGNT YY NEKFKG RATLTA DKSTS TAYMQLS SLRSEDT AVYFC ARG VYYFD YWGQG TTVTVS S | D IVMT QSPSS LSA SVGD RVTITCK ASQNV RTNVAWYQ QKPGKAPK ALIYSASYRY SGVPDRFTGSGSGTD FTLTIS SLQ PEDFADYFCQQY NSYPRTFGGGT KVEI K |
Basiliximab | Whole mAb | G1 | Kappa | Approved | NFD | QVQLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSS | QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIK | na | na | 1mim:HL/3iu3:AB:CD:HL | null | null | 1,996 | 1997 | IL2RA | Cerimon Pharmaceuticals;Novartis | Renal transplant rejection;Transplant rejection | na | Ulcerative colitis;Uveitis | na | null | QV QLQ QSG TVLA RPGA SVKMSCK ASGYS FTRYWMHWIK QRPGQGL EWIGAI YPGNSDTSYNQK F EGK AKLTAVT SAST AYMEL SSLTHEDS AVYYC SRDYG YYFDF WGQG TTLTVS S | QI VS TQSP AIMS ASPGE KVTMTCS ASSSRS YMQWYQ QKPGTSPK RWIYD TSKLASGVP ARFS GSGSGT SYSLTISS MEAEDA ATYYCHQ RSS YTF GGGT KLEI K |
Batoclimab | Whole mAb | G1 | Lambda | Phase-III | Active | QLLLQESGPGLVKPSETLSLTCTVSGGSLSSSFSYWVWIRQPPGKGLEWIGTIYYSGNTYYNPSLKSRLTISVDTSKNHFSLKLSSVTAADTAVYYCARRAGILTGYLDSWGQGTLVTVSS | SYVLTQSPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSASNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL | na | na | null | null | null | 2,019 | 2020 | FCGRT | Immunovant Sciences | na | Graves' Ophtalmopathy;Myasthenia gravis;Autoimmune disorders;Neuromyelitis optica;Idiopathic thrombocytopenic purpura | na | na | null | Q LLLQE SGPGL V KPSE TLSLTCTV SGGSLSSS FSYWVWIR QPPGKGL EWIGTIYYS GNT Y YNPSLK SRLTISVD TSKN HFSLKLSS VTAADT AVYYCAR RAG ILTGYL DSWGQG TLVTVS S | S YVLT QSPS VSV APGQ TARITC GGNNIGSK SVHWYQ QKPGQAP VLVVY DDSDRPSGIPE RFSA SNSGN TATLTISRVE AGDE ADYYCQVWD SSSD HVVFG GGT KLTV L |
Bavituximab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLQQSGPELEKPGASVKLSCKASGYSFTGYNMNWVKQSHGKSLEWIGHIDPYYGDTSYNQKFRGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCVKGGYYGHWYFDVWGAGTTVTVSS | DIQMTQSPSSLSASLGERVSLTCRASQDIGSSLNWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYVSSPPTFGAGTKLELK | na | na | null | null | null | 2,006 | 2007 | Phosphatidylserine | Avid Bioservices;IMV;Massachusetts General Hospital;Merck Sharp & Dohme;Peregrine Pharmaceuticals;University of Arizona;University of Texas Southwestern Medical Center;University of Texas M. D. Anderson Cancer Center | na | Non-small cell lung cancer;Glioblastoma;Liver cancer;Solid tumours | Breast cancer;Malignant melanoma;Pancreatic cancer;Brain cancer;Hepatitis C;HIV infections;Rectal cancer;Viral haemorrhagic fevers;Influenza virus infections;Prostate cancer | na | null | EV QLQ QSGPELEKPGA SVKLSCK ASGY SFTGYNMNWVK QSHGK SLEWIGHI DPYYGDTSYNQK F RG KATLTVD KSSST AYMQLKS LTSEDS AVYYCV KGGYYG HWYFDVW GAGT TVTVS S | DI QMT QSPSS LS ASLGE RVSLTCR ASQDIGSS LNWLQQ GPDGT IKRLIYAT SSLDSGVPK R FSGSRSGSD YSLTISS LESEDF VDYYCLQYV SSPPTFGAGT KLEL K |
Bavunalimab | Bispecific Mixed mAb and scFv | G1;na | Kappa;Kappa | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFDDAWMSWVRQAPGKGLEWVAEISTKANNHATYYAESVKGRFTISRDDSKSSVYLQMNSLRAEDTAVYYCTRLATWDWYFDVWGQGTTVTVSS | DIVLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKPPKLLIYAASELESGIPARFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPFTFGSGTKLEIK | EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVSFISYDGNYKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGHLGPFDLWGQGTMVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK | None;None | None;None | None;None | 2,020 | 2021 | LAG3;CTLA4 | Xencor | na | na | Solid tumours | na | Bavunalimab is the new name for Pavunalimab (PL125). (Jun '22) Corrected IMGT H25 S->A. | E VQLVES GGG LV QPGG SLRLSC AASGFTFDDA WMSWVR QAPGKGL EWVAEIST KANNH ATYYAES VKG RFTISR DDSKS SVYLQMN SLRAEDT AVYYCTR LATWD WYFDV WGQG TTVTVS S | D IVLT QSPSS LSA SVGD RVTITCRA SQS V DYDGD SYMNWYQ QKPGKPP KLLIYAA SELESGIP ARFS GSGSGTD FTLTISS LQPEDF ATYYCQ QSNEDPF T FGSGT KLEI K |
Bebtelovimab | Whole mAb | G1 | Lambda | Approved | Active | QITLKESGPTLVKPTQTLTLTCTFSGFSLSISGVGVGWLRQPPGKALEWLALIYWDDDKRYSPSLKSRLTISKDTSKNQVVLKMTNIDPVDTATYYCAHHSISTIFDHWGQGTLVTVSS | QSALTQPASVSGSPGQSITISCTATSSDVGDYNYVSWYQQHPGKAPKLMIFEVSDRPSGISNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTSSAVFGGGTKLTVL | na | na | 7mmo:AB:DE | null | null | 2,022 | na | SARS-CoV-2 Spike RBD | Eli Lilly;AbCellera | COVID-19 | na | na | na | null | Q ITLK ESGP TLV KPTQ TLTLTCTF SG FSLSIS G VGVGWLR QPPGKA LEWLALIYW DDDKRYSPSLK SRLTIS KDTSKN QVVLKMTN IDPVDTA TYYC AHHS ISTIF DHWGQG TLVTVS S | QSALTQPA SV SGSPGQ SITISCTA TSSDVGD YNYVSWYQ QHPGKAP KLMIFEV SDRPSGISNRFSGSKSGN TASLTIS GLQAEDEAD YYCSS YTTSS AVF GGGT KLTV L |
Becotatug | Whole mAb | G1 | Kappa | TBC | Active | QVQLQESGPGLVKPSETLSLTCTVSGFSLSNYDVHWVRQAPGKGLEWLGVIWSGGNTDYNTPFTSRLTISVDTSKNQFSLKLSSVTAADTAVYYCARALDYYDYEFAYWGQGTLVTVSS | EIVLTQSPDFQSVTPKEKVTITCRASQSIGTNIHWYQQKPDQSPKLLIKYASESISGIPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQNNEWPTSFGQGTKLEIK | na | na | null | null | null | 2,022 | na | EGFR | TBC | TBC | TBC | TBC | TBC | null | QV QLQE SGPGL V KPSE TLSLTCTV SGF S LSNY DVHWVRQ APGKGL EWLGVIWS GGNTDYNTPF TSRLTISVD TSKN QFSLKLSS VTAADT AVYYCA RALDYYD YEFAYW GQG TLVTVS S | E IVLTQ SPDFQSVTPKE KVTITCR ASQSIGT NIHWYQ QKPDQSP KLLIKYA SESISGIPSRFSGSGSGT DFTLTINS LEAED AA TYYCQ QNNEWPTSFGQGT KLEI K |
Bedinvetmab | Canine Whole mAb | G2 | Lambda | Approved | Active | EVQLVESGGDLVKPGGSLRLSCVASGFTFSSHGMHWVRQSPGKGLQWVAVINSGGSSTYYTDAVKGRFTISRDNAKNTVYLQMNSLRAEDTAMYYCAKESVGGWEQLVGPHFDYWGQGTLVIVSS | QSVLTQPTSVSGSLGQRVTISCSGSTNNIGILGASWYQLFPGKAPKLLVYGNGNRPSGVPDRFSGADSGDSVTLTITGLQAEDEADYYCQSFDTTLGAHVFGGGTHLTVL | na | na | null | null | null | 2,018 | 2019 | Canine NGFB | na | na | Canine lupus familiaris | na | na | (June '22: Corrected FWL1 sequence) | E VQLVE SGGD LV KPGG SLRLSCV ASG FTFS SHG MHWVRQ SPGKG LQWVAVIN SGGSS TYYTD AVKG RFTISR DNAKN TVYLQMN SLRAEDT AMYYCAK ESVGGW EQLV GPHFD Y WGQG TLVIVS S | QSVLTQPT SVS GSLGQ RVTISC SGSTNN IGILGASWYQL FPGKAP KLLVY GNGNRPSGVPDRFSGADSGD SVTLTITG LQAEDEAD YYCQS FDTTLGA HVF GGGT HLTV L |
Befovacimab | Whole mAb | G2 | Lambda | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMDWVRQAPGKGLEWVSSIRGSRGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLYRYWFDYWGQGTLVTVSS | SYELTQPPSVSVSPGQTARITCSGDNLPKYYAHWYQQKPGQAPVVVIFYDVNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWWSSTPVFGGGTKLTVL | na | na | null | null | null | 2,019 | 2020 | TFPI | na | na | Haemophilia | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSS YGM DWVR QAPGKG LEWVSSIR GSRGS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCARLYRYWFDY WGQG TLVTVS S | SYELTQPPS VSV SPGQ TARITC SGDNLP KY YAHWYQ QKPGQAP VVVIFYD VNRPSGIPERFSGSNSGN TATLTIS GTQAMDEAD YYCQAWW SSTPVFGGGT KLTV L |
Begelomab | Whole mAb | G2b | Kappa | Phase-II/III | Active | QVQLQQSGAELVKPGASVKLSCKASGYTFRSYDINWVRQRPEQGLEWIGWIFPGDGSTKYNEKFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCARWTVVGPGYFDVWGAGTTVTVSS | QIVLTQSPAIMSASPGEKVTITCSASSSVSYMNWFQQKPGTSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSYPNTFGGGTKLEIK | na | na | null | null | null | 2,014 | 2015 | DPP4 | ADIENNE | na | Graft-versus-host disease | na | na | null | Q VQLQQ SGA ELV KPGA SVKLSCK ASGY TFRSYDINWVR QRPEQGL EWIGWIF PGDGSTKYNEKFKG KATLTT DKSSS TAYMQLSR LTSEDS AVYFCARWTVV GPGY FDVW GAG TTVTVS S | Q IVLT QSP AIMS ASPGE KVTITCS ASSS VSYMNWF QQKPGTSP KLWIYS TSNLASGVP ARFS GSGSGT SYSLTISR MEAEDA ATYYCQQ RSSYPNTFGGG TKLEI K |
Belantamab | Whole mAb ADC | G1 | Kappa | Approved | Active | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLDNWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKLLIYYTSNLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIK | na | na | null | null | null | 2,017 | 2018 | TNFRSF17 | GlaxoSmithKline | Multiple myeloma | na | na | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT F S NYWMHWVR QAPGQG LEWMGATYR GHSDTYYNQKFK GRVTITA DKSTS TAYMELS SLRSEDT AVYYCA RGA IY DG YDVL DNWGQG TLVTVS S | DIQMTQSPSS LSA SVGD RVTITCS ASQD ISNYLNWYQ QKPGKAP KLLIYYT SNLHSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YRKLPWTFGQGT KLEI K |
Belimumab | Whole mAb | G1 | Lambda | Approved | Active | QVQLQQSGAEVKKPGSSVRVSCKASGGTFNNNAINWVRQAPGQGLEWMGGIIPMFGTAKYSQNFQGRVAITADESTGTASMELSSLRSEDTAVYYCARSRDLLLFPHHALSPWGRGTMVTVSS | SSELTQDPAVSVALGQTVRVTCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCSSRDSSGNHWVFGGGTELTVL | na | na | 5y9k:HL/5y9j:HL/6fxn:OP:QR:MN:FG:HI:DE | null | 6erx:HI:DE:QR:MN:FG:OP | 2,003 | 2004 | TNFSF13B | Assistance Publique Hopitaux de Paris;Cancer Trials Australia;GlaxoSmithKline;Hospital for Special Surgery;Human Genome Sciences;North Shore-Long Island Jewish Health System;University of Alabama at Birmingham;University of Pennsylvania;University of Wisconsin-Madison;Washington University School of Medicine;Cambridge Antibody Technology | Systemic lupus erythematosus;Lupus nephritis | Anti-neutrophil cytoplasmic antibody-associated vasculitis;Myositis;Emphysema;Membranous glomerulonephritis;Myasthenia gravis;Renal transplant rejection;Systemic scleroderma;Graft-versus-host disease | Waldenstrom's macroglobulinaemia;Rheumatoid arthritis;Sjogren's syndrome | CAT Phage Display | null | Q VQLQQ SGA EVK KPGS SVRVSCK ASGGTFNNN AINWVR QAPGQGL EWM GG IIP MFGTA KY SQNFQG RVAITA DESTG TASMELSS LRSEDT AVYYCA RSRD LLLF PHHALSPWGRG TMVTVS S | SSELTQDPA VSVA LGQ TVRVTC QGDS LR S Y YA SW Y QQKPGQAP VLVIY GKNNRPSGIPDRFSGSSSGN TASLTIT GAQAEDEA DYYCSSR DSSGN HWVF GGGT ELTV L |
Belrestotug | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGVIGPSGASTSYAQKFQGRVTLTRDTSTSTVYMELSSLRSEDTAVYYCARDHSDYWSGIMEVWGQGTTVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVRSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYFSPPWTFGGGTKVEIK | na | na | null | null | null | 2,022 | na | TIGIT | GlaxoSmithKline;iTeos Therapeutics | na | Multiple myeloma;Haematological malignancies;Solid tumours;Non-small cell lung cancer | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYYMHWVR QAPGQG LEWMGVI GPSGASTSYA QK FQG RVTLTR DTSTS TVYMELS SLRSEDT AVYYCA RDHSDYW SGIMEVW GQGT TVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSV RSS YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QYFSPPWTFGGGT KVEI K |
Beludavimab | Whole mAb | G1 | Kappa | Phase-I/II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYQGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGTKVEIK | na | na | null | 7jx3:AB:CD:HL/6ws6:AB:CD:EF/6wps:CD:FG:HL/6wpt:DE:HL/7bep:HL:GI/7l0n:CD:AB/7r6x:AB/7r6w:AB/7sob:GI:HJ:NO/7soc:HL/7tly:AB;7tm0:JK:LM:NO/7tn0:BA:CD | null | 2,021 | 2022 | SARS-CoV-2 Spike RBD | GlaxoSmithKline | na | COVID-19 | na | Beludavimab and Sotrovimab have identical Fvs | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGYPFT SYGISWVRQ APGQGL EWMGWISTY QGNTNY AQKF QG RVTMTT DTSTTT GYMELRRL RSDDT AVYYCAR DYTRGA WF GE SLI GG F DNWGQG TLVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQ TV SST SLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QHDT SLTF GGG TKVEI K |
Bemarituzumab | Whole mAb | G1 | Kappa | Phase-III | Active | QVQLVQSGAEVKKPGSSVKVSCKASGYIFTTYNVHWVRQAPGQGLEWIGSIYPDNGDTSYNQNFKGRATITADKSTSTAYMELSSLRSEDTAVYYCARGDFAYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQGVSNDVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHSTTPYTFGQGTKLEIK | na | na | null | null | 7sob:GI:HJ:NO/7soc:HL | 2,017 | 2018 | FGFR2 | Five Prime Therapeutics;ZAI Lab | na | Gastric cancer | Oesophageal cancer;Solid tumours | POTELLIGENT Technology | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASG YIFTTYNVHWVRQ APGQG LEWIGSI YPDNGDTSYNQNFKG RATITA DKSTS TAYMELS SLRSEDT AVYYCA RGD FAYW GQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCK ASQGVSND VAWYQ QKPGKAP KLLIYSASYRY TGVPSRFSGSGSGT DFTFTIS SLQ PEDIAT YYC QQHSTTPY T FGQGT KLEI K |
Bempikibart | Whole mAb | G1 | Kappa | TBC | Active | EVQLVESGGGLVQPGRSLRLSCAASGFTFDDHAMHWVRQAPGKGLEWVSGISWNSRGIGYADSVKGRFTIFRDNAKNSLYLQMNSLRAEDTALYYCAKDEYSRGYYVLDVWGQGTTVTVSS | AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLWITFGQGTRLEIK | na | na | null | null | null | 2,022 | na | IL7R | TBC | TBC | TBC | TBC | TBC | null | E VQLVES GGG LV QPGR SLRLSC AASGF TF DDHA MHWVRQ APGKGL EWVSGISW NSRGI G YADSVKG RFTIFR DNAKN SLYLQMN SLRAEDT ALYYCA KDEYSRG YYVLDV WGQG TTVTVS S | AI QLT QSPSS LSA SVGD RVTITCR ASQG ISSALAWYQ QKPGKAP KLLIYD ASSLESGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ FNSYP LWITF GQGT RLEI K |
Benralizumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCGTSEDIINYLNWYQQKPGKAPKLLIYHTSRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYTLPYTFGQGTKVEIK | na | na | null | null | null | 2,009 | 2010 | IL5RA | AstraZeneca;Cincinnati Children's Hospital Medical Center;Kyowa Hakko;Kyowa Hakko Kirin;McMaster University;MedImmune;National Jewish Medical and Research Center;BioWa | Asthma | Chronic obstructive pulmonary disease;Nasal polyps;Atopic dermatitis;Churg-Strauss syndrome;Hypereosinophilic syndrome;Rhinosinusitis;Eosinophilic gastroenteritis | Skin disorders | POTELLIGENT Technology | null | E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYVIHWVR QRPGQG LAWMGYI NPYNDGTKYNE RF KG KVTITS DRSTS TVYMELS SLRSED TAVYLC GREGI RYYGLL GDYWGQG TLVTVS S | DIQMTQSPSSL SA SVGD RVTITC GT SEDIINYLNWYQ QKPGKAP KLLIYH TSRLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQ QGY T LP YT FGQGT KVEI K |
Bentracimab | Whole mAb | G1 | Lambda | Phase-III | Active | QVQLQESGAEVKKPGSSVRVSCKASGGTFDSYSIHWVRQAPGQGLEWMGGIIPAFGTLSSAQDFQARVTISADKSTSTAYMELSGLRSEDTAVYYCARGSFDYYFWSASHPPNDALAIWGQGTLVTVSS | QSVVTQPPSVSAAPGQKVTISCSGSNSDIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLAITGLQAGDEADYYCGTWLYDRAVGLFGGGTKVTVL | na | na | 5alb:HL | null | 5alc:HL | 2,020 | 2021 | AR-C124910XX | MedImmune;AstraZeneca;PhaseBio | na | Haemorrhage (reversal of effects of ticagrelor) | na | na | null | Q VQLQE SGA EVK KPGS SVRVSCK ASGGTFD SYSIHWVRQ APGQG LEWMGGIIP AFGTLSSAQD FQARVTISA DKSTS TAYMEL SGLRSEDT AVYYC ARGS FDYYFWS ASHPPND ALAIW GQG TLVTVS S | QSV V TQPPSVSAAPGQ KVTISC SGSNSDIGN NYVSWYQQ LPGTAP KLLIY DNNKRPSGIPDRFSGSKSGTS ATLAIT GLQAGDEAD YY CG TWL YDRAVGL FGGGT KVTV L |
Benufutamab | Whole mAb | G1 | Kappa | Phase-I/II | Active | EVQLQQSGAEVVKPGASVKLSCKASGFNIKDTFIHWVKQAPGQGLEWIGRIDPANTNTKYDPKFQGKATITTDTSSNTAYMELSSLRSEDTAVYYCVRGLYTYYFDYWGQGTLVTVSS | EIVMTQSPATLSVSPGERATLSCRASQSISNNLHWYQQKPGQAPRLLIKFASQSITGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQGNSWPYTFGQGTKLEIK | na | na | 6t3j:AB:FG | null | null | 2,019 | 2020 | TNFRSF10B | Genmab;VU University Medical Center;iDD Biotech | na | Solid tumours;Multiple myeloma | na | na | null | E VQLQQ SGA EVV KPGA SVKLSCK ASGFNIKD TFIHWVK QAPGQG LEWIGRI DPANTNTKYDPKFQG KATITT DTSSN TAYMELS SLRSEDT AVYYCV RG LYTYYFD YWGQG TLVTVS S | E IVMT QSPA TLSV SPGE RATLSCRA SQSISNN LHWYQ QKPGQAP RLLIKF ASQS ITGI P ARF SGSGSGT EFTLTISS LQSED FAVYYC QQGNSWP YTF GQGT KLEI K |
Bepranemab | Whole mAb | G4 | Kappa | Phase-II | Active | EVQLQESGPGLVKPSETLSLTCTVSGFSLTSNDIAWIRQPPGKGLEWMGTIWTDGSTNYNTAVQSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHRLYYGAFDYWGQGTMVTVSS | DIVMTQTPLSLSVTPGQPASISCRSSQSLEYSDGYTYLEWYLQKPGQSPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQATHNPYTFGQGTKLEIK | na | na | null | null | null | 2,019 | 2020 | MAPT | UCB BioPharma | na | Progressive supranuclear palsy (PSP);Alzheimer's Disease | na | na | (June '22: Removed duplicate residue from FWL3) | E VQLQE SGPGL V KPSE TLSLTCTV SG FS LTSND IAWIR QPPGKGL EWMGTIWT DGSTNYNTA VQSRVTISVD TSKN QFSLKLSS VTAADT AVYYC ARHR LYYGAFD YWGQG TMVTVS S | DI VMT QTP LSLSV TPGQP ASISCR SSQ SLEY SDGY TYLEWYL QKPGQSP QLLIYEVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCFQA THNPYTFGQG TKLEI K |
Berlimatoxumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | ELQLQESGPGLVKPSETLSLTCTVSGGSISSGSYYWDWIRQPPGKGLEWIGNIYKSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARERGMHYMDVWGKGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSINSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQFDPPFTFGGGTKVEIK | na | na | 5k59:HL:EF | null | null | 2,017 | 2018 | Toxin A | Adimab;Arsanis;X4 Pharmaceuticals | na | na | Staphylococcal infections | na | null | EL QLQE SGPGL V KPSE TLSLTCTV SGGSISSGS YYWDWIR QPPGKGL EWIGNIYK SGS TYY NPSLKS RVTISVD TSKN QFSLKLSS VTAAD T AVYYCA R ERGM HYMDV WGKG TTVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQS INSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQ QQFDPPF T FGGGT KVEI K |
Bermekimab | Whole mAb | G1 | Kappa | Preregistration | Active | QVQLVESGGGVVQPGRSLRLSCTASGFTFSMFGVHWVRQAPGKGLEWVAAVSYDGSNKYYAESVKGRFTISRDNSKNILFLQMDSLRLEDTAVYYCARGRPKVVIPAPLAHWGQGTLVTFSS | DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYEASNLETGVPSRFSGSGSGSDFTLTISSLQPEDFATYYCQQTSSFLLSFGGGTKVEHK | na | na | null | null | null | 2,018 | 2019 | IL1A | XBiotech Inc. | na | Colorectal cancer;Cachexia;Atopic dermatitis;Acne vulgaris;Hidradenitis suppurativa;Non-small cell lung cancer;Plaque psoriasis;Systemic scleroderma;Type 2 diabetes mellitus;Vascular restenosis;Pancreatic cancer | Haematological malignancies | na | null | Q VQLVES GGG VV QPGR SLRLSCT ASGF TFSMFGVHWVRQ APGKG LEWVAAVSY DGSNK YYAESV KG RFTISR DNSKN ILFLQM DSLRLEDT AVYYC ARGRP KVVIP APLAHWGQG TLVTF SS | DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWY QQKPGKAP KLLIYE ASNLETGVPSRFSGSGSGSD FTLTIS SLQP EDFA TYYC QQTSS FLLSF GGGT KVE HK |
Bersanlimab | Whole mAb | G1 | Lambda | Phase-II | Discontinued | EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVAFIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYSGWYFDYWGQGTLVTVSS | QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYDNNNRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQSYDSSLSAWLFGGGTKLTVL | na | na | null | null | null | 2,017 | 2018 | ICAM1 | BioInvent International | na | na | Multiple myeloma | n-CoDeR | null | E VQLLES GGG LV QPGG SLRLSC AASGF TF SNA WMSWVR QAPGKGL EWVAFIWY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAR YSG WYFD YWGQG TLVTVS S | QSVLTQPPSASGTPGQ RVTISCT GSSSNIGAG YDVHWYQ QLPGTAP KLLIY DNNNRPSGVPDRFSGSKSGTS A SLAI SGLRSEDEA D YYCQ SYDSS LSA WLF GGGT KLTV L |
Betifisolimab | Whole mAb | G1 | Kappa | Phase-I/II | Active | QVQLVQSGAEVKKPGASVKLSCKASGYIFTTYWMHWVKQRPGQGLEWIGMIQPNSGGTKYNEKFKKKATLTVDKSISTAYMELSRLTSDDTAVYYCARGAGTVDYFDYWGQGSTLTVSS | DIVLTQSPASLAVSVGQRATITCRASESVDIYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTINPVEAQDTATYYCQQSTEDPYTFGGGTKLEIK | na | na | null | null | null | 2,022 | na | CD274 | MabSpace Biosciences;Transcenta Holding | na | Solid tumours | Haematological malignancies | na | null | Q VQLVQ SGA EVK KPGA SVKLSC KASG YIFTTYWMHWVK QRPGQGL EWIGMI QPNSGGTKYNEKFKK KATLTV DKSI STAYME L S RLTSDDT AVYYCA RGAGT VDYFD YWGQGS TLTVS S | D IVLT QSPA SLAVS VGQ RATITCR ASE SVDIY GNS FMHWYQ QKPGQPP KLLIYRA SNLESGIP ARF SGSGSRT DFTLTIN PVEAQDT ATYYCQQ STEDPYTFGGG TKLEI K |
Bevacizumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK | na | na | 1bj1:HL:KJ | null | 6bft:AB:HL/1cz8:HL:YX | 2,000 | 2001 | VEGFA | All Ireland Cooperative Oncology Research Group;ARCAGY/GINECO Group;Austrian Breast & Colorectal Cancer Study Group;Bayer;Beth Israel Deaconess Medical Center;Breast Cancer Research Foundation;Brigham and Women's Hospital;Bristol-Myers Squibb;Cancer and Leukemia Group B;Cancer Research UK;Chugai Pharmaceutical;Cincinnati Children's Hospital Medical Center;Dana-Farber Cancer Institute;Duke University;European Organisation for Research and Treatment of Cancer;European Thoracic Oncology Platform;Genentech;Hackensack University Medical Center;Hoosier Cancer Research Network;Indiana University School of Medicine;Japan Breast Cancer Research Group;M. D. Anderson Cancer Center;Massachusetts General Hospital;Medical University of South Carolina;Melanoma Research Foundation Breakthrough Consortium;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);National Comprehensive Cancer Network;NCIC Clinical Trials Group;North Central Cancer Treatment Group;NSABP Foundation;Ohio State University Medical Center;Peter MacCallum Cancer Centre;Roche;Royal Marsden NHS Foundation Trust;Sanofi;Sarcoma Alliance for Research through Collaboration;SCRI Development Innovations;South Eastern European Research Oncology Group;Spanish Cooperative Group for Digestive Tumour Therapy;Spanish Lung Cancer Group;Stanford University School of Medicine;SWOG;The Catalan Institute of Oncology;UNICANCER;University College London;University of Alabama at Birmingham;University of Arkansas System;University of California Davis;University of Iowa;University of Oklahoma;University of Tennessee;University of Texas M. D. Anderson Cancer Center;US Oncology Research;West German Study Group;Xijing Hospital | Breast cancer;Cervical cancer;Colorectal cancer;Glioblastoma;Glioma;Non-small cell lung cancer;Ovarian cancer;Renal cell carcinoma;Fallopian tube cancer;Peritoneal cancer | Head and neck cancer;Biliary cancer;Brain metastases;Endometrial cancer;Ewing's sarcoma;Gynaecological cancer;Hodgkin's disease;Intestinal cancer;Liver cancer;Liver metastases;Malignant melanoma;Meningioma;Multiple myeloma;Neuroblastoma;Neurofibromatoses;Rectal cancer;Soft tissue sarcoma;Solid tumours;Urogenital cancer;Neoplastic meningitis;Sarcoma | Carcinoid tumour;Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Eye disorders;Gastric cancer;Gastrointestinal stromal tumours;Mesothelioma;Oesophageal cancer;Pancreatic cancer;Prostate cancer;Small cell lung cancer | na | null | E VQLVES GGG LV QPGG SLRLSC AASGY TFTN YGM NWVRQ APGKGL EWVGWIN TYTGEPT YA ADFKR RFTFSL DTSKS TAYLQMN SLRAEDT AVYYCA KYPHYYGSS HWYFDV WGQG TLVTVS S | DIQMTQSPSS LSA SVGD RVTITCS ASQD ISNYLNWYQ QKPGKAP KVLIYFT SSLHSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YSTVPW T FGQGT KVEI K |
Bexmarilimab | Whole mAb | G4 | Kappa | Phase-I/II | Active | QVTLKESGPTLVKPTQTLTLTCSFSGFSLSTSGMGIGWIRQPPGKALEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARHYGYDPYYAMDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCTASSSVSSSYLHWYQQKPGKAPKLLIYRTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCHQYHRSPPTFGQGTKLEIK | na | na | null | null | null | 2,019 | 2020 | STAB1 | Faron Pharmaceuticals | na | Solid tumours;Cancer;Immunocompromised infections;Pertussis;Tuberculosis | na | na | null | QV TLK ESGP TLV KPTQ TLTLTCSF SG FSLS TSGM GIGWIR QPPGKA LEWLAHIWW DDDKRYNPALK SRLTIS KDTSKN QVVLTMT NMDPV DTATYYCARH YGYDPY YAMD YWGQG TLVTV SS | E IVLTQ SPG TLSL SPGE RATLSCTA SSSVSSS YLHWYQ QKPGKAP KLLIYRT SNLASGVPS R FSGSGSGTD YTLTISS LQPE DF ATYYCHQ YHRSPPTFGQGT KLEI K |
Bezlotoxumab | Whole mAb | G1 | Kappa | Approved | NFD | EVQLVQSGAEVKKSGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIFYPGDSSTRYSPSFQGQVTISADKSVNTAYLQWSSLKASDTAMYYCARRRNWGNAFDIWGQGTMVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSTWTFGQGTKVEIK | na | na | 4np4:HL:IM | null | null | 2,012 | 2013 | Toxin A | Medarex;University of Massachusetts Medical School;Merck & Co;Merck Sharp & Dohme | Clostridium difficile | na | na | Medarex HuMAb Mouse | null | E VQLVQ SGA EVK KSGE SLKISC KGSGY SFTSYWIGWVRQ MPGKGL EWMGIF YPGDSSTR Y SPSFQG QVTIS ADKSVN TAYLQWSS LKASDT AMYYCAR RRNWGNA FDIW GQG TMVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYC Q QYGSS TWTF GQGT KVEI K |
Bifikafusp | Whole mAb Fusion | E | Kappa | Phase-III | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK | na | na | null | null | null | 2,010 | 2011 | FN extra domain B | Philogen | na | Non-small cell lung cancer;Diffuse large B-cell lymphoma;[With onfekafusp] Malignant melanoma;[With onfekafusp] Basal cell cancer;[With onfekafusp] Squamous cell cancer;[With onfekafusp] Solid tumours | Malignant melanoma;Renal cell carcinoma;Solid tumours;Atherosclerosis;Head and neck cancer;Pancreatic cancer | na | Radretumab+Bifikafusp+Onfekafusp have identical V domains | E VQLLES GGG LV QPGG SLRLSC AASGF TFSSFSMSWVR QAPGKG LEWVSSIS GSSGT TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KPFPYFDYWGQG TLVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS SSFLAWY Q QKPGQAP RLLIYYA SSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QTGRIPPTFGQGT KVEI K |
Bimagrumab | Whole mAb | G1 | Lambda | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSSYINWVRQAPGQGLEWMGTINPVSGSTSYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWFDYWGQGTLVTVSS | QSALTQPASVSGSPGQSITISCTGTSSDVGSYNYVNWYQQHPGKAPKLMIYGVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCGTFAGGSYYGVFGGGTKLTVL | na | na | 5nhr:HL:AB | 5nhw:HL/5nh3:HL:IM/5ngv:HL | null | 2,012 | 2013 | ACVR2B | MorphoSys;Novartis | na | Cachexia;Muscular atrophy;Type 2 diabetes mellitus | Inclusion body myositis | MorphoSys HuCAL Phage Display | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSSYINWVR QAPGQG LEWMGTI NPVSGSTSY AQKF QG RVTMT RDTS ISTAYMELSR LRSDDT AVYYC ARGG WFDY WGQG TLVTVS S | QSALTQPA SV SGSPGQ SITISCT GTSSDVGS YNYVN WYQ QHPGKAP KLMIYGVS KRPSGVSNRFSGSKSGNT ASLTIS GLQAEDEAD YYC G T FAGGS YYGVF GGGT KLTV L |
Bimekizumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYNMAWVRQAPGKGLEWVATITYEGRNTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPPQYYEGSIYRLWFAHWGQGTLVTVSS | AIQLTQSPSSLSASVGDRVTITCRADESVRTLMHWYQQKPGKAPKLLIYLVSNSEIGVPDRFSGSGSGTDFRLTISSLQPEDFATYYCQQTWSDPWTFGQGTKVEIK | na | na | null | null | null | 2,013 | 2014 | IL17A | UCB | Plaque psoriasis | Ankylosing spondylitis;Psoriatic arthritis;Hidradenitis suppurativa;Ulcerative colitis;Axial spondylarthritis | Psoriasis;Rheumatoid arthritis | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TF SDY NMAWVRQ APGKG LEWVATITY EGRN TYYRD SVKG RFTISR DNAKNS LYLQMNS LRAEDT AVYYCA SPPQYYEGS IYRLWFAH WGQG TLVTVS S | AI QLT QSPSS LSA SVGD RVTITCR ADE SVRTLMHWYQ QKPGKAP KLLIYLVS NSEIGVPDRFSGSGSGTD FRLTIS SLQPE DFA TYYCQ QTWSDPWTFGQGT KVEI K |
Bintrafusp | Whole mAb Fusion | G1 | Lambda | Approved | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS | QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL | na | na | 4nki:HL/5grj:HL | null | null | 2,015 | 2016 | CD274 | AIO Studien gGmbH;Array BioPharma;Chong Kun Dang;Dana-Farber Cancer Institute;Debiopharm;eFFECTOR Therapeutics;EMD Serono;Forty Seven;Fred Hutchinson Cancer Research Center;Gachon University Gil Medical Center;Hellenic Cooperative Oncology Group;Hospices Civils de Lyon;Johannes Gutenberg-University Mainz;M. D. Anderson Cancer Center;Merck KGaA;National Cancer Institute (USA);National Cancer Institute Slovakia;Netherlands Cancer Institute;Pfizer;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syndax Pharmaceuticals;Transgene;University College London;University of Birmingham;University of California San Diego;University of Iowa;Vaccinex;Vanderbilt-Ingram Cancer Center;VAXIMM;Verastem Oncology;Washington University School of Medicine | Merkel cell carcinoma;Urogenital cancer | Renal cell carcinoma;Breast cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Bladder cancer;Endometrial cancer;Fallopian tube cancer;Germ cell and embryonal neoplasms;Gestational trophoblastic disease;Glioblastoma;Haemangiosarcoma;Intestinal cancer;Leiomyosarcoma;Nasopharyngeal cancer;Neuroendocrine tumours;Osteosarcoma;Peripheral T-cell lymphoma;Peritoneal cancer;Prostate cancer;Recurrent respiratory papillomatosis;Small cell lung cancer;Solid tumours;Squamous cell cancer;Thymoma;Liposarcoma;Lymphoma;Oropharyngeal cancer;Pancreatic cancer;Acute myeloid leukaemia;Follicular lymphoma;Hodgkin's disease;Liver cancer;Meningioma | na | Human Phage Display | Avelumab and Bintrafusp have identical V domains | E VQLLES GGG LV QPGG SLRLSCA ASGF TFSSYIMMWVRQ APGKG LEWVSSI YPSGG ITFYAD TVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCARIK LGT VTTVDY WGQG TLVTVS S | QSALTQPA SV SGSPGQ SITISCT GTSSDVGG YNYVSWYQ QHPGKAP KLMIYD VSNRPSGVSNRFSGSKSGN TASLTIS GLQAEDEAD YYCSS YTSSST RVF GTGT KVTV L |
Birtamimab | Whole mAb | G1 | Kappa | Phase-III | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMYWIRQAPGKGLEWVARIRSKSNNYAIYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARPYSDSFAYWGQGTLVTVSS | DVVMTQSPLSLPVTPGEPASISCRSSQSLVHSTGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPFTFGGGTKVEIK | na | na | null | null | null | 2,018 | 2019 | SAA1 | Neotope Biosciences;Onclave Therapeutics;Prothena | na | na | Amyloid light-chain amyloidosis | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFNTYAMYWIRQ APGKG LEWVARIR SKSNN YAIYYA DSVKD RFTISR DDSKNS LYLQMN SLKTEDT AVYYCA RPYSDS FAYW GQG TLVTVS S | DV VMT QSPLSLPVTPGEPA SISC RSSQ SLVH STGNT YLHWYLQ KPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYC SQSTHVP FTF GGG TKVEI K |
Bleselumab | Whole mAb | G4 | Kappa | Phase-II | Discontinued | QLQLQESGPGLLKPSETLSLTCTVSGGSISSPGYYGGWIRQPPGKGLEWIGSIYKSGSTYHNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCTRPVVRYFGWFDPWGQGTLVTVSS | AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPTFGQGTKVEIK | na | na | null | null | null | 2,015 | 2016 | CD40 | Kirin Brewery;Astellas Pharma;Kyowa Hakko Kirin | na | na | Transplant rejection;Plaque psoriasis;Focal segmental glomerulosclerosis;Renal transplant rejection | na | null | QL QLQE SGPGLLKPSE TLSLTCTV SGGSISSPGY YGGWIR QPPGKGL EWIGSIYK SGSTYHNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYC TRP VVRYFGWF DPWGQG TLVTVS S | AI QLT QSPSS LSA SVGD RVTITCR ASQG ISSALAWYQ QKPGKAP KLLIYD ASNLESGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ FNSYPTFGQGT KVEI K |
Blinatumomab | Bispecific T-Cell Engager | na;na | Kappa;Kappa | Approved | Active | QVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSS | DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIK | DIKLQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS | DIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK | None;None | None;None | None;None | 2,008 | 2009 | CD19;CD3E | Amgen;Astellas Pharma;M. D. Anderson Cancer Center;Merck & Co;Micromet Inc;National Cancer Institute (USA);University of California Davis | Precursor B-cell lymphoblastic leukaemia-lymphoma | Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma;Richter's syndrome;Burkitt's lymphoma | Chronic lymphocytic leukaemia | BiTE Technology | null | Q VQLQQ SGA ELV RPGS SVKISCK ASGY AFSS Y WMNWVK QRPGQGL EWIGQI WPGDGDTNYNG KFKGKATLTA DESSS TAYMQLS SLASEDS AVYFCAR RETT T VG RYYYAMD YWGQG TTVTVS S | DI QLT QSPA SLAVS LGQ RATISCK ASQ SV DYDGD SYLNWYQ QIPGQPP KLLIYD ASNL V SGIPPRFSGSGSGTD FTLNIH PVE K VDAA TYHCQ QSTEDPWTFGGG TKLEI K |
Blontuvetmab | Canine Whole mAb | G2 | Kappa | Unknown | Active | QVQLQQSRAELVRPGASVTLSCKPSGYTFTDYEVHWVKQTPVHGLEWIGAIDPETGGTADNQKFKGKAILTADKSSSTAYMELRSLTSEDSAVYYCTNFVDVWGTGTTVTVSS | DVVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSGNQKNYLAWYQQKPGQSPRLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVFYCQQYYNYPLTFGGGTHL | na | na | null | null | null | 2,015 | 2016 | MS4A1 | Aratana Pharmaceuticals | na | Canine B-cell lymphoma | na | na | null | QV QLQQ S RAELV RPGA SVTLSC KPSGY TF TD YEVHWVK QTPVHG LEWIGAI DPETGGTADNQ KF KG KAILTA DKSSS TAYMELRS LTSEDS AVYYCTNFVDV WGTG TTVTVS S | DV VMS QSPS SLAVS VGE KVTMSC KSSQ SLLY SGNQKN YLAWYQ QKPGQSP RLLIYWA STRESGVPDR F TGSGSGTD FTLTISS VK A E D LAVFYCQQ YYNYPL T FGGGTHL |
Blosozumab | Whole mAb | G4 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKVSGFPIKDTFQHWVRQAPGKGLEWMGWSDPEIGDTEYASKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGDTTYKFDFWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDVHTAVAWYQQKPGKAPKLLIYWASTRWTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSDYPWTFGGGTKVEIK | na | na | null | null | null | 2,011 | 2012 | SOST | Eli Lilly | na | Postmenopausal osteoporosis | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCKV SGFPIKDT FQHWVR QAPGKGL EW MGWSDPEIGDTE YAS KFQG RVTMT EDTSTDT AYMELS SLRSEDT AVYYC ATGDT TYKFDF WGQG TTVTVS S | DIQ MT QSPSS LSA SVGD RVTITCK ASQDV H TAVAWYQ QKPGKAP KLLIYWA STRWTGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQ QYSDYPW T FGGG TKVEI K |
Bococizumab | Whole mAb | G2 | Kappa | Phase-III | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGEISPFGGRTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARERPLYASDLWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQRYSLWRTFGQGTKLEIK | na | na | 3sqo:HL | null | null | 2,013 | 2014 | PCSK9 | Halozyme Therapeutics;Pfizer | na | na | Cardiovascular disorders;Hypercholesterolaemia;Hyperlipidaemia | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYYMHWVR QAPGQGL EWMGEI SPFGGRTNYNEKF KSRVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RERPL YA SDLWGQG TTVTVS S | DIQ M TQSPSS LSA SVGD RVTITCR ASQG ISSALAWYQ QKPGKAP KLLIYSASYRY TGVPSRFSGSGSGTD FTFTIS SLQ PEDIATYYCQ QRY SLWRT FGQGT KLEI K |
Boserolimab | Whole mAb | G1 | Kappa | Phase-II | Active | EIQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWINTNTGEPTYAEEFKGRFTFTLDTSISTAYMELSSLRSEDTAVYYCAREGDAMDYWGQGTTVTVSS | EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPKRWIYDTSKLASGVPARFSGSGSGTDYSLTISSLEPEDFAVYYCQQWNSYPFTFGQGTKLEIK | na | na | null | null | null | 2,022 | na | CD27 | Bionovion;Merck Sharp & Dohme | na | Non-small cell lung cancer;Small cell lung cancer | Solid tumours | na | null | E IQLVQ SGA EVK KPGA SVKVSCK ASGY TFTN YG MNWVK QAPGQG LKWMGWIN TNTGEPT YAEEF KG RFTFTL DTSI STAYMELS SLRSEDT AVYYCA REGDAMDYWGQG TTVTVS S | E IVLTQ SPA TLSL SPGE RATLSCS ASSS VSYMHWYQ QKPGQAPK RWIYD TSKLASGVP ARFS GSGSGTD YSLTIS SLEPED FAVYYCQ QWNSYPF TF GQGT KLEI K |
Botensilimab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYAESVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVGLFGPFDIWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSRYLGWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK | na | na | null | null | null | 2,020 | 2021 | CTLA4 | Agenus | na | Solid tumours | na | na | null | E VQLVES GGG LV KPGG SLRLSC AASGF TFSS Y SMNWVR QAPGKG LEWVSS ISSSSS YIYYAE SVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCARV G LF GPF DI WGQG TLVTV SS | E IVLTQ SPG TLSL SPGE RATLSCR ASQS VSRY LGWY QQKPGQAP RLLIYG ASTRATGIPDRFSGSGSGTD FTLTITR LEP ED FAVYYCQ QYGSSPW T FGQGT KVEI K |